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Abstract  
 
Attentional processes and capacities are central to cognitive performance. 
Cortically projecting cholinergic neurons of the basal forebrain are essential 
components of the neural systems underlying attentional function; however 
exactly how the cholinergic system supports attentional performance remains 
unknown.  Our current model suggests that transient (scale of seconds) 
increases in acetylcholine (ACh) release in the prefrontal cortex foster the 
detection of predictive cues, and that the generation of such transients is dictated 
by glutamate released from mediodorsal thalamic afferents and the stimulation of 
ionotropic glutamate receptors. The studies that informed this model were based 
on data from anesthetized preparations and animals performing relatively simple 
instrumental tasks.  Two of the primary aims of the work going in to my 
dissertation were to utilize a novel technique with a high degree of temporal 
precision to record glutamatergic and cholinergic activity in animals performing a 
sustained attention task (SAT) to characterize how these two major 
neurotransmitter systems interact to support attentional performance.  The major 
results from these studies are that in contrast to signal detection per se, transient 
increases in ACh release mediate performance on signal trials requiring a shift 
from cue-independent to cue-dependent processing.  The pattern of glutamate 
release in task performing animals suggests that in addition to recruiting 
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cholinergic mechanisms, glutamate plays an additional role in signaling choice.  
Finally our work revealing the interactions between cholinergic and glutamatergic 
mechanisms additionally predict and explain the observation that α4β2 nAChR 
agonists more robustly enhance attentional performance in the distractor version 
of the SAT than the non-selective nAChR agonist nicotine. The results from 
these studies suggest the limited beneficial effects of nicotine are due to its 
stimulation of long lasting release events that are unlikely to support specific 
cognitive operations.  Collectively, the work included here has 1) redefined the 
role of cholinergic transient in attention 2) begun to explore the complex interplay 
between glutamatergic and cholinergic signaling in cognitive performance 3) 
demonstrated that by building upon our knowledge of the functions of and  
interactions between these two systems we can predict the pro-attentional 
efficacy of putative cognition enhancers 
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Chapter I 
 
Introduction 
  
 Consider the case of a radar operator or air traffic controller whose job is 
to monitor a screen for the appearance of a small dot which signifies a plane or a 
submarine.  So long as there is no signal, their thinking would be largely 
internally driven, perhaps focused upon remaining alert, thinking about how long 
it has been since the last time they saw a signal, or even when they might expect 
the next one to appear on screen. However, when this important signal does 
appear, their thinking would shift to recalling what the signal means in regards to 
the behaviors they now need to engage in order to successfully complete their 
job.   
 Most successful goal-directed behavior requires such shifts between cue-
independent and cue-oriented attention (Burgess, Dumontheil, & Gilbert, 2007). 
There is some evidence from human imaging studies. For example, switching 
between internally and externally-focused processing increases activation in 
executive control areas, most notably the right rostrolateral prefrontal cortex 
(Brodmann’s Area, BA, 10) (Burgess, et al., 2007; Henseler, Kruger, Dechent, & 
Gruber; McCaig, Dixon, Keramatian, Liu, & Christoff). Patients with lesions of this 
region perform well on executive tasks that rely exclusively on external cues, 
although they have difficulty in situations that require shifts between self-directed 
and cue-oriented behavior (Burgess, Veitch, de Lacy Costello, & Shallice, 2000; 
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Volle, Gonen-Yaacovi, Costello Ade, Gilbert, & Burgess). Furthermore, this 
region is dysfunctional in disorders associated with impairments in cue 
processing and organized behavior (Cools, Rogers, Barker, & Robbins, 2010; 
Laurens, Kiehl, Ngan, & Liddle, 2005).  However on the whole, the neuronal 
mechanisms mediating such shifts are not well understood.      
 My work has been predominantly focused upon identifying neural 
mechanisms in the prefrontal cortex (PFC) that support attentional function.  
Over the years (and particularly the last month), we have redefined our thinking 
about how exactly these mechanisms support cognitive performance, culminating 
with the hypothesis that transient increases in prefrontal acetylcholine (ACh) 
release are critical for the shift from cue-independent to cue-dependent or cue-
oriented processing.  We have also begun to explore how prefrontal 
glutamatergic and cholinergic systems interact synergistically to support this 
cognitive operation. 
  The discussion to follow will begin with a background on the cholinergic 
system; its general organization and evidence from previous studies that support 
its role as a central component of the brain’s attentional networks.  Next I will 
discuss of the existing evidence regarding interactions between cholinergic and 
glutamatergic mechanisms in the prefrontal cortex.  Finally, I will discuss the 
behavioral paradigm employed by all the studies included in this dissertation, the 
sustained attention task.  
 
Cholinergic systems in cognition, focus on attention and prefrontal cortex 
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Ascending cholinergic projections originate from nuclei located within the 
brainstem and basal forebrain (Mesulam, Mufson, Wainer, & Levey, 1983). 
Brainstem cholinergic neurons are located in the pedunculopontine nucleus and 
laterodorsal tegmental nucleus, and go on to innervate several thalamic nuclei 
and as well as the basal forebrain (Rotter & Jacobwitz, 1981; Rye, Saper, Lee, & 
Wainer, 1987; Woolf & Butcher, 1986), and are hypothesized to play an 
important role in initiating REM sleep (Maloney et al., 1999). The term “basal 
forebrain” refers to cholinergic neurons that are present in the horizontal and 
vertical limbs of the diagonal band, the magnocellular neurons of the nucleus 
basalis (nBM), substantia innominata, the magnocellular preoptic nucleus, and 
the nucleus ansa lenticularis (Armstrong, Saper, Levey, Wainer, & Terry, 1983; 
Mesulam, et al., 1983; Woolf, Eckenstein, & Butcher, 1983). These neurons 
collectively provide the major source of the cholinergic innervation of the 
hippocampus, amygdala, and neocortex. Given the functional significance of 
these terminal fields, the cholinergic contribution to cognitive processes is 
overwhelmingly discussed in terms of these cortically projecting cholinergic 
neurons.  
In primates, the primary source of cholinergic innervation of the PFC 
arises from the nBM. The corresponding source of neocortical cholinergic input in 
the rodent includes neurons within the nBM and substantia innominata 
(Armstrong, et al., 1983; Luiten, Gaykema, Traber, & Spencer, 1987; Mesulam, 
et al., 1983).  The axons of cortically projecting basal forebrain cholinergic 
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neurons innervate all layers of the PFC, with particularly dense innervation of 
layers I, III, and V (Mrzljak & Goldman-Rakic, 1992, 1993; Mrzljak, Levey, & 
Goldman-Rakic, 1993; Mrzljak, Pappy, Leranth, & Goldman-Rakic, 1995). This 
pattern of innervation has been suggested to be indicative of a lamina-specific 
cholinergic modulation of cognitive function (Lysakowski, Wainer, Bruce, & Hersh, 
1989).   
 ACh exerts its influence through actions on two major types of receptors in 
the central nervous system; ionotropic nicotinic receptors and metabotropic 
muscarinic receptors.  Nicotinic acetylchoine receptors (nAChRs) are non-
selective cation channels with a pentameric structure composed of α (2-10) and 
β (2-4) subunits. According to their binding affinity, nAChRs can be divided into 
two major classes: receptors with high affinity (nmol) for nicotine and receptors 
with high affinity for α-bungarotoxin.  In the mammalian central nervous system, 
the most prevalent conformations of nAChRs are the α4β2 nAChR (high binding 
affinity for nicotine), and the homomeric α7 nAChR (high binding affinity for α-
bungarotoxin) (Berg & Conroy, 2002; Dajas-Bailador & Wonnacott, 2004; 
Dickinson, Kew, & Wonnacott, 2008; Galzi & Changeux, 1995; Galzi, Edelstein, 
& Changeux, 1996; Wonnacott, 1997).  The other class of receptor is the 
muscarinic, which is G-protein coupled, and 5 forms have been identified (M1-M5) 
with M1 and M2 being the most commonly discussed in terms of their function in 
the brain.  Muscarinic receptors vary in which G-protein they are bound, and thus 
their effects on membrane potential. For example, M1 receptors are Gq coupled 
and typically described as being located post-synaptically with binding having a 
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net stimulatory effect. M2 receptors function primarily as presynaptic 
autoreceptors, are Gi coupled, and upon stimulation have a net inhibitory effect 
(Mrzljak, et al., 1993). 
Early attempts at parsing out the functional relevance of basal forebrain 
cholinergic projections to the cortex relied primarily upon determining the effects 
of systemic administration of non-selective cholinomimetic compounds. modeling 
the effects of endogenously released ACh via the exogenous application of the 
neurotransmitter in discrete brain regions. For example, in the auditory cortex 
that the administration of ACh, when paired with a repeated, pure-tone stimulus, 
enhanced stimulus-specific neuron activity, or “signal”, while having no effect on 
spontaneous firing, or “noise” (Metherate & Weinberger, 1989). Furthermore, 
ACh can enhance responses to previously “weak” signals by decreasing the 
threshold needed to elicit an action potential (Metherate, Ashe, & Weinberger, 
1990; Metherate & Weinberger, 1989, 1990). This phenomena is believed to be 
mediated through muscarinic, specifically M1, receptors, and reflects the ability of 
the cholinergic system to heighten the signal-to-noise ratio for relevant sensory 
stimuli (Hasselmo & Bower, 1992). As local infusions of ACh are unlikely to 
replicate concentrations of the transmitter resulting from endogenous release, the 
aforementioned studies failed to provide a physiological measure of cholinergic 
modulation. Therefore, the demonstration that basal forebrain stimulation can 
similarly enhance and suppress neural response in the auditory cortex elicited by 
thalamocortical activation (Metherate and Ashe, 1991) further emphasizes the 
role of ACh in modulating the signal-to-noise ratio. More recently, this preliminary 
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research has been reinterpreted as indicative of the ability of ACh to both 
enhance ascending input to the cortex from sensory systems and suppress 
spontaneous spiking (Hasselmo and McGaughy, 2004). Thus, the combined 
effects of ACh in cortical regions can shape the integration of stimuli into 
associative networks involved in attention (Hasselmo and McGaughy, 2004). Via 
stimulation of nAChRs and muscarinic receptors, ACh generally has been 
suggested to gate information flow between the cortical layers, allowing for 
greater attentional selectivity for salient stimuli (Munk, Roelfsema, Konig, Engel, 
& Singer, 1996; Xiang, Huguenard, & Prince, 1998). 
 Primary evidence in support of the importance of forebrain cholinergic 
systems in attention was derived from studies employing the immunotoxin 192-
IgG saporin, which selectively targets the p75 neurotrophic receptor-expressing 
cholinergic neurons of the basal forebrain (Book, Wiley, & Schweitzer, 1992; 
Wiley, Oeltmann, & Lappi, 1991). Selective removal of cortical cholinergic inputs 
profoundly and permanently impairs performance in tasks designed to tax 
attentional processes and capacities (McGaughy, Dalley, Morrison, Everitt, & 
Robbins, 2002; McGaughy, Kaiser, & Sarter, 1996; Sarter, Hasselmo, Bruno, & 
Givens, 2005), specifically the ability to report the presentation of a predictive 
stimulus, while sparing the ability to indicate its absence (McGaughy, et al., 
1996). 
 Further evidence for cholinergic modulation of attentional capacities was 
provided by studies utilizing in vivo microdialysis. These investigations have 
demonstrated that engagement in and performance of an attention task evokes 
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increases in fronto-cortical ACh release, while performance in tasks designed to 
control for motor behavior, reward presentation and reward retrieval do not 
(Arnold, Burk, Hodgson, Sarter, & Bruno, 2002).  Further, ACh release is 
augmented in the face of increased demands on attentional control, such as 
those imposed by disruption of prefrontal cholinergic neurotransmission, 
attentional fatigue, or a distracting stimulus (Himmelheber, Sarter, & Bruno, 2001; 
Kozak, Bruno, & Sarter, 2006; Parikh, Kozak, Martinez, & Sarter, 2007; Sarter, 
Gehring, & Kozak, 2006; Sarter & Paolone, 2011; St Peters, Demeter, Lustig, 
Bruno, & Sarter, 2011)  
Also important to note is that the function cortical cholinergic inputs in 
attentional performance is right lateralized; unilateral depletion of right 
hemispheric cholinergic inputs re-creates the profound impairments in attention 
observed in animals with bilateral cholinergic depletion (Martinez & Sarter, 2004) 
a finding concordant with the focus on right-hemispheric networks supporting 
attentional function in human imaging studies (Arrington, Carr, Mayer, & Rao, 
2000; Corbetta, Kincade, Ollinger, McAvoy, & Shulman, 2000; Demeter, 
Hernandez-Garcia, Sarter, & Lustig, 2011).  Additionally, studies have shown that 
in attention task performing, but not non-performing, animals, the capacity of the 
high affinity choline transporter, the rate limiting step of readily releasable ACh 
reserves, is augmented in the right prefrontal cortex (PFC) as a result of task 
performance, but not left PFC (Apparsundaram, Martinez, Parikh, Kozak, & 
Sarter, 2005).  
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 The long standing notion of the cholinergic system as a modulator also 
carried with it ideas about its primary mode of neurotransmission; a slow, tonic 
state of release, as measured by microdialysis, that gradually and globally 
fluctuates over the course of task performance to modulate the state of cortical 
networks in response to demands on attentional/cognitive control (Paolone, 2010; 
Sarter, et al., 2006; Sarter & Paolone, 2011). With the optimization of enzyme 
selective biosensors capable of measuring ACh release on a sub-second time 
scale in task-performing animals, it has been revealed that in addition to this 
tonic mode, there is a fast, phasic mode of cholinergic neurotransmission that 
operates on a scale of seconds.  These “transient” increases in cholinergic 
activity are evoked by attention capturing cues (Parikh, et al., 2007).  Further, 
these cue-evoked release events are observed in the medial PFC (mPFC) and  
not in cortical control regions (e.g. primary motor cortex) (Parikh, et al., 2007). 
Together, these findings suggested a significant departure from the traditional 
conceptualization of cholinergic function; temporally and regionally specific 
signaling coincident with discrete cognitive and behavioral functions.  
 
Interplay of cholinergic and glutamatergic mechanisms in the prefrontal 
cortex 
Neuropharmacological studies provided the first level of insight into the 
local mPFC circuitry that underlies the generation of these transient cholinergic 
release events. For example, infusions of nicotinic receptor (nAChR) agonists 
into the mFPC can evoke the release of both glutamate and ACh (Gioanni, et al., 
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1999; Lambe, Picciotto, & Aghajanian, 2003; Parikh, Ji, Decker, & Sarter, 2010; 
Parikh, Man, Decker, & Sarter, 2008).  Further work in anesthetized animals has 
revealed that nAChR agonist-evoked increases in ACh release are attenuated by 
blockade of glutamatergic AMPA and NMDA receptors. Removal of mediodorsal 
thalamic input to the mPFC abolishes nAChR stimulated ACh release and 
suggests that this thalamic nuclei is a primary source of glutamatergic inputs to 
the mPFC.  Cholinergic mechanisms also modulate glutamatergic afferents. For 
example, stimulation of α4β2 nAChRs evokes glutamate release.  Furthermore, 
nAChR agonist evoked glutamate release is robustly attenuated in B2 -/- mutant 
mice (Parikh, et al., 2010; Parikh, et al., 2008).  The combined evidence allows 
for the development of a model of prefrontal circuitry. Our working model 
suggests that cholinergic transients are the result of glutamate release from the 
mediodorsal thalamus stimulating ionotropic glutamate receptors located on the 
terminals of cholinergic inputs, resulting in the production of the cholinergic 
transient.  In turn, glutamate release is also modulated by ACh through actions at 
α4β2 nAChR located on the axons of the thalamic inputs.   
 
Measuring attention in rats: the Sustained Attention Task (SAT) 
  
 An illustration of the task that will be employed in all of the experiments 
included in my dissertation is provided in Figure 1.1.   The sustained attention 
task (SAT) is comprised of two trial types, signal and non-signal.  The 
presentation of signal and non-signal trials is randomized.  Trials are separated 
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by a variable inter-trial interval (ITI) of 9±3 s to prevent animals from timing 
events.  On a signal trial, a centrally located light on the intelligence panel is 
turned on for a variable amount of time (500,50,or 25 ms).  Two seconds after 
the cue light is extinguished, the two response levers, located on either side of a 
reward port located beneath each the cue light, are extended into the operant 
chamber.  A press on one of these levers, for example, the lever located to the 
left of the reward port, results in the presentation of a water reward, and is scored 
as a Hit.  A press on the right lever is not rewarded, and scored as a Miss.  In 
either case, after the response, the levers are retracted. If no response is made 
within 4 s, the levers are retracted and the trial is scored as an omission.  On a 
non-signal trial, the levers are extended into the chamber after the ITI.  A press 
on the right lever is rewarded and scored as a correct rejection (CR).  A press on 
the left lever is not rewarded, and scored as a false alarm.  Again, after a press 
on either lever, they are retracted, which triggers the ITI to begin.  Sessions 
consist of ~200 trials, taking a total of 40 minutes.  In addition, a houselight 
located at the back of the operant chamber remains illuminated throughout the 
task, preventing the animal from being able to monitor for changes in chamber 
luminescence and thereby necessitating maintained focus on the intelligence 
panel.  This task has been validated as a measure of sustained attention in rats 
(McGaughy & Sarter, 1995), and has been adapted for use in human subjects 
(Demeter, Sarter, & Lustig, 2008). Further, the distractor version of the task 
(dSAT, houselight flashing on and off at a rate of 0.5 Hz) was recently selected 
by the Cognitive Neuroscience Treatment Research to Improve Cognition in 
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Schizophrenia (CNTRICS) group for research on the control of attention 
(Nuechterlein, Luck, Lustig, & Sarter, 2009).  
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Figure 1.1 
Main components of the sustained attention task (SAT). The task includes two 
types of trials, signal and non-signal.  On a signal trial, after a variable inter-trial 
interval (9±3 s; ITI) a centrally located cue light on the intelligence panel is 
illuminated (500, 50, or 25 ms).  After 2 s, 2 response levers are extended into 
the chamber.  If the animal presses the correct lever (left in the above example) it 
is rewarded and the trial is scored as a hit (incorrect responses are scored as 
misses).  On a non-signal trial, after the ITI the 2 levers are extended into the 
chamber and the animal must press the opposite lever (right), and then is 
presented with reward.  Correct responses are scored as correct rejections (CR), 
incorrect as false alarms (FA) 
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Present Studies 
  
 The work that has gone in to my dissertation has been guided by two 
overlapping aims. The first is largely oriented towards basic science, and 
identifying the constituent neurobiological mechanism(s) that underlie 
fundamental aspects of cognition.  Previous studies examining cholinergic-
glutamatergic interactions in the mPFC were done in anesthetized animal 
preparations and in animals performing relatively simple tasks. By employing a 
novel method for measuring neurotransmission in near real-time, I have 
monitored fluctuations in both acetylcholine (ACh) and glutamate release in the 
medial prefrontal cortex (mPFC) of animals performing the SAT.  By relating the 
changes in activity of these major chemical messaging systems to one another, I 
have added to our understanding of the neural substrates that support attentional 
performance and underlie shifts between cue-independent and cue-dependent 
processing.  The second is to build upon this knowledge to explain and predict 
the pro-attentional efficacy of compounds with putative cognition enhancing 
abilities.  Of the many compounds developed for the treatment of the cognitive 
impairments associated neuropsychiatric and neurodegenerative disorders, few 
have been met with great success in the clinical settings (Sarter, 1991, 2006; 
Sarter, Hagan, & Dudchenko, 1992a, 1992b; Sarter, Parikh, & Howe, 2009). 
Here, we have demonstrated that selective targeting of a subpopulation of 
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nicotinic acetylcholine receptors (nAChR) enhances attentional performance by 
facilitating the shift between cue-independent and cue-dependent processing.    
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Chapter II 
 
TRANSIENT INCREASES IN PREFRONTAL CHOLINERGIC 
NEUROTRANSMISSION MEDIATE THE SHIFT FROM CUE INDEPENDENT 
TO CUE DEPENDENT ATTENTION. 
 
Summary 
  Cortical cholinergic inputs are necessary for performance in a variety of 
cognitive tasks, particularly those tapping attentional capacities (McGaughy, et 
al., 2002; McGaughy, Decker, & Sarter, 1999; McGaughy, et al., 1996). However 
precisely how the cholinergic system contributes to such performance has 
remained elusive. A recently developed method for in vivo measurement of 
acetylcholine (ACh) at a sub-second temporal resolution has led to new insights 
in our understanding of its function (Parikh, et al., 2007). The objective of this 
series of experiments was to test the hypothesis that 1) in animals performing a 
sustained attention task (SAT) involving signal and non-signal events, transient 
increases in medial prefrontal (mPFC) cholinergic activity mediate performance 
on trials requiring signal detection (Hits), and 2) removal of cholinergic inputs to 
the prefrontal cortex impairs signal detection performance.  In agreement with 
our first hypothesis, we discovered that seconds-long increases in ACh are 
selective to signal trials resulting in Hits.  Upon further analysis we discovered 
that not all detected cues evoke ACh release, but that the presence of such a 
release event depends upon the previous trial type.  Specifically, ACh increases 
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were only observed on Hits if preceded by a non-signal response on the previous 
trial. In support of our second hypothesis, detection performance was only 
impaired in this subset of Hit trials in animals with prefrontal cholinergic lesions.  
These results suggest that rather than mediating detection per se, signal-evoked 
increases in ACh release contribute to the ability of prefrontal networks to shift 
from cue-independent attentional processing, to cue-dependent processing.  It is 
further hypothesized that a complementary or even primary function of the event 
is to act as a reporter or learning signal, refining or strengthening the associative 
networks that afford such shifts. 
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Introduction 
 
Cholinergic projections from the nucleus basalis of Meynert (medial wall of 
globus pallidus), substantia innominata (ventral to the globus pallidus) and the 
horizontal limb of the diagonal band (collectively termed basal forebrain, BF) to 
the neocortex have long been implicated as central to normal cognitive 
performance.  Further, dysfunction within this ascending system has been linked 
to the cognitive impairments seen in schizophrenia, ADHD, and age-related 
cognitive decline (Bartus, Dean, Beer, & Lippa, 1982; Deutsch, 1971; Everitt & 
Robbins, 1997; Hasselmo & Sarter, 2010; McGaughy, et al., 2002; McGaughy, et 
al., 1999; McGaughy, et al., 1996; Sarter, et al., 2005; Sarter, Parikh, et al., 
2009). A substantial literature places a special emphasis on this system as a 
mediator of attentional performance (Hasselmo & Sarter, 2010; McGaughy, et al., 
2002; McGaughy, et al., 1999; McGaughy, et al., 1996; Sarter, et al., 2005; 
Sarter, Parikh, et al., 2009; Turchi & Sarter, 1997). In tasks that require reporting 
either the presence or absence of a cue, cortex-wide removal of cholinergic 
inputs selectively impairs the ability to utilize predictive cues to guide responding, 
while performance on non-cued trials remains intact (McGaughy, et al., 1996). 
Such evidence suggests that the role of the cortical cholinergic input system in 
attention is the optimization of signal detection and integration of stimuli into 
associative networks (Hasselmo & McGaughy, 2004; McGaughy, et al., 1999; 
McGaughy, et al., 1996; Parikh, et al., 2007; Sarter, et al., 2005). However, the 
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exact mechanisms through which cortical cholinergic inputs contribute to such 
performance remain poorly understood.  
Attempts at clearly delineating the role of cortical cholinergic inputs have 
long been impeded by the lack of a technique capable of selectively measuring 
ACh release in real-time. Taking advantage of recent advances in enzyme-based 
biosensor technology, our lab has been involved in the development of a method 
for measuring ACh release at a high temporal resolution (<1s) in task-performing 
animals. This technique combines fixed-potential amperometry with in vivo 
electrochemistry to measure the changes in extracellular choline derived from the 
hydrolysis of ACh on a sub-second time scale. The ability of this method to 
measure choline generated by the hydrolysis of newly released ACh has been 
demonstrated previously (Parikh, et al., 2004). For example, removal of 
cholinergic inputs to the recording region or administration of neostigmine, an 
acetylcholinesterase (AChE) inhibitor, blocks KCl-evoked choline signals in vivo. 
Similarly, choline signals generated by pre-synaptic blockade of muscarinic 
receptors are blocked by tetrodotoxin (Parikh, et al., 2004). In these experiments, 
animals were anesthetized during the recording phase.  
Initial attempts at employing this electrochemical method in task 
performing animals (Parikh, et al., 2007) utilized a relatively simple cued-
appetitive response task that could be manually controlled and as such helped 
avoid many of the sources of electrostatic noise present in an typical operant 
chamber (motorized retractable levers, solenoids, etc.). In the task, a randomly 
occurring visual cue (every 90 ± 30 s) predicted the subsequent availability of 
  23 
reward. Detected cues, as defined by an interruption of interoceptively guided 
behavior (such as grooming) and the initiation of reward seeking behavior 
(approach to the reward port location) evoked transient (seconds-long) increases 
in medial prefrontal (mPFC) cholinergic activity.  On trials were cues did not 
evoke this behavioral response no change in cholinergic activity was observed 
even though animals were prompted to approach and retrieve reward with the 
sound of it being placed in the receptacle. These cue-evoked release events 
were selective to the mPFC, and were not observed in cortical control regions 
(e.g. primary motor cortex). Further, cue detection behavior in this task is 
dependent upon the generation of an ACh release event, as both selective 
lesions of prefrontal cholinergic inputs and pharmacological attenuation of 
transients impairs detection performance (Gietzen, 2010; Parikh, et al., 2007). 
Taken together, the results of these experiments provided the first 
evidence that temporally and regionally specific changes in cholinergic activity 
are critical for a specific cognitive process (i.e., cue detection). It is important to 
note that in this context, and for the remainder of the discussion, cue detection 
refers to “…the entry of information concerning the presence of a signal into a 
system that allows the subject to report the existence of the signal by an arbitrary 
response indicated by the experimenter”  (Posner, Snyder, & Davidson, 1980), 
and is therefore a distinctly cognitive as opposed to a sensory operation.  
In the last 4 years, we have been able to further optimize our 
electrochemical recording techniques, and can now successfully record from 
animals performing fully automated operant tasks where fluctuations in current 
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evoked by task relevant stimuli (such as a detected cue) are rather small (2-5 pA). 
The cued appetitive response task is notably simple, and did not involve defined 
demands on attention which limited the interpretation of the results. The following 
experiments use a more stringent behavioral paradigm that requires higher 
cognitive demand to address this issue. Experiment 1 measured changes in 
mPFC cholinergic activity on a sub-second time scale in animals performing the 
sustained attention task (Figure 1; SAT). The task involves signal detection (in 
one out of four trial types) and, in contrast to the cued appetitive response task, 
was specifically designed to incorporate parameters that tax attentional 
capacities (McGaughy & Sarter, 1995; Parasuraman, 1987). Specifically, this 
task employs a relatively short ITI and randomly occurring signal and non-signal 
trials (each of which requires a response on discreet response manipulanda). 
These conditions necessitate a level of constant cognitive engagement. Incorrect 
responses to signal and non-signal events (misses and false alarms, respectively) 
require a lever press similar to correct responses (hits/correct rejections). 
Therefore, comparisons of changes in cholinergic activity between trial types are 
not confounded by different response topographies or levels of motivation (the 
failure to response within 4 s after the insertion of levers is counted as an 
omission; omissions are relatively rare and occur in less than 10% of trials). 
Finally, correct responses on both signal and non-signal trials are rewarded, 
providing an additional control for potential contributions of reward expectation 
and retrieval to increases in cholinergic activity. It should be noted that the use of 
the SAT in the present experiments is not to imply that cortical cholinergic activity 
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does not represent a critical component to other types of attention (divided, 
selective) as has been described previously (Turchi & Sarter, 1997). However, 
the specific hypotheses being tested in the proposed experiment address the 
involvement of cholinergic inputs in signal detection. As cue detection is integral 
for above chance performance in the SAT, it is an ideal paradigm for testing our 
specific hypothesis.  To address the issue of the necessity of specifically 
prefrontal, as opposed to all cortical, cholinergic inputs for performance in this 
task an additional, preliminary, experiment assessed the affects of selective, 
bilateral prefrontal cholinergic deafferentation on detection performance. As both 
mPFC and orbitofrontal cortex have been implicated in supporting performance 
in this task (Lustig, 2011; Parikh, et al., 2007; Sarter, et al., 2005; Sarter, Parikh, 
et al., 2009; St Peters, et al., 2011), lesions were targeted to cover both regions 
of the frontal pole. 
 
Materials and Methods 
Subjects 
 
 Subjects were male Wistar rats approximately 60 days old (200-300g) at the 
onset of training. Animals were kept on a 14:10 light/dark cycle in a temperature 
and humidity-controlled vivarium. Water was only available as a reward during 
testing and for 30 min upon the completion of the training/testing session. Food 
was available ad libitum. All training and testing took place during the light cycle 
between 0800-1700 hours. Animals were maintained in accordance with the NIH 
guide for the Care and Use of Animals and experiments were conducted in 
  26 
accordance with protocols approved by the University of Michigan Committee on 
Use and Care of Animals (UCUCA). 
 
Apparatus  
 
Rats were trained in one of twelve operant chambers (Med Associates, 
Georgia, Vt., USA) enclosed within a sound attenuating box and equipped with a 
fan to conceal any residual background noise. Each chamber was equipped with 
a water port located between two retractable levers. A central panel light was 
located at the front of each chamber above the water port. Additional panel lights 
were located above each lever. A house light was positioned at the back of the 
chamber. All training and testing programs were executed with a PC running 
Med-PC software (V. IV).  
Electrochemical recordings were conducted in a 12” X 10” X 17” wooden 
operant chamber completely shielded by copper-wire mesh and equipped with 
two retractable levers constructed of fiberboard normally employed for electrical 
insulation. The receptacle used for water delivery was constructed from copper. 
The entire assembly was connected to an electrical ground. The relative location 
of the central panel light is the same as in the training chambers. The 
background illumination provided by the houselight, and the change in luminance 
following the presentation of the signal were kept constant between training and 
testing environments. 
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Pre-surgical training procedures 
 
 Animals were trained in the same chamber daily.  In the first stage of training 
the two response levers were extended into the operant chamber and remained 
so throughout the session. A press on either lever led to access to 0.1 mL of 
water (FR-1 schedule), with the rule that if, for example, at any time the number 
of presses on the left lever was 5 greater than the number of presses on the right, 
the left lever becomes inactive until the right lever is pressed. This rule was 
designed to discourage the development of a lever or side bias. This phase of 
training continued until animals reached the criterion of 120 rewards per session 
(approximately 45 min) for two consecutive days.  
In the second stage of training, animals had to discriminate between 
signal (illumination of central panel light) and non-signal (no illumination of 
central panel light) trials. It is important to note that the houselight prevents 
animals from being able to monitor for simple changes in chamber brightness, 
and must direct their focus to the intelligence panel.  Each session included 160 
trials equally divided between signal and non-signal. Correct responses were 
rewarded with water. On a signal trial, the signal light was turned for 1 second. 
Two seconds later the response levers were extended into the chamber. A press 
on the left lever was considered correct, and scored as a hit. A press on the right 
lever was scored as a miss. On non-signal trials, a press on the right lever was 
considered correct, and the trial scored as a correct rejection. A press of the left 
lever was considered incorrect, and scored as a false alarm (note: half of all 
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animals were trained with non-signal and signal response levers in the reverse 
position). The levers were retracted after being depressed regardless of whether 
the response was correct or incorrect. An omission was reported when animals 
failed to press either lever after four seconds, at which time both levers were 
retracted. Incorrect responses were followed by correction trials identical to the 
previous trial. After three consecutive errors on correction trials, animals were 
given a forced choice trial. If the error had occurred on a signal trial, the left lever 
alone was extended while the central panel light and the light directly above the 
correct lever remain illuminated. Only the right lever is extended into the chamber 
in the case of a non-signal trial.  The inter trial interval (lTI) was 12±3 s during 
this stage of training. Performance criterion for this stage was >70% hits and 
correct rejections for three consecutive sessions.  
In the third stage of training the correction and forced trials were dropped, 
and the ITI was decreased to 9±3 s. The signal duration remained fixed at 1 s 
and sessions consisted of a total of 162 trials. As with the previous stage, 
criterion for advancement was >70% hits and correct rejections for three 
consecutive sessions. 
In the final version of the task, signal duration was shortened and varied 
(500, 50, or 25 ms). Training sessions were to a total of 162 trials, half signal and 
half non-signal. Performance was analyzed in 3 blocks of trials, each consisting 
of 54 trials. Signal and non-signal trials were presented in a pseudo-randomized 
order. Animals were trained on the final version of the task until performance 
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reached a plateau. Only animals with >70% hits to 500 ms signals and >70% 
correct rejections were employed in the present experiments.  
 
Preparation and Calibration of Choline-Selective Microelectrodes 
 
 Multi-site microelectrodes were purchased from the Center for Microelectrode 
Technology at the University of Kentucky (Quanteon LLC, Nicholasville, KY; see 
Fig. 2.1 for a depiction of the measurement scheme).  Each electrode array 
featured four 15x333 m Platinum-recording sites arranged in side-by-side pairs. 
The pairs of electrodes were separated by 100 µm, and 30 µm separated sites in 
a pair.  Connecting lines and recording sites were imprinted on a ceramic base ~ 
125 µm thick. The connecting lines were coated with a layer of polyamide for 
insulation. The entire assembly was connected to circuit board. Microelectrodes 
were modified for recordings in freely moving animals by soldering four 2 cm 
pieces of enamel-coated magnet wire (30 ga) to gold terminals on the circuit 
board, each of which was connected to an individual recording site. The other 
end of the wire was connected to a female gold-pin. The gold-pins were inserted 
into a miniature 9-pin connector and glued to the microelectrode assembly using 
epoxy. The Ag/AgCl reference electrodes were constructed of 0.008” diameter 
silver wire (A-M Systems, Carlsberg, WA) soldered to a gold-pin, which was also 
inserted into the connector.  
After assembly, electrodes were dip-coated with Nafion™ and then baked 
at 170°C for 4 minutes to repel anionic interferents from the platinum sites.  The 
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bottom pair of recording sites were then coated with choline oxidase (CO) that 
had been cross-linked with a bovine serum-albumin (BSA)-glutaraldehyde 
mixture (1% CO, 1% BSA and 0.125% glutaraldehyde) using a 1µL syringe 
(Hamilton, Reno, NV, USA). The remaining two recording sites were coated with 
the BSA-glutaraldehyde solution alone and served to record background activity. 
Enzyme-coated microelectrodes were allowed to cure of 48-72 hrs in a 
desiccator prior to calibration.  
Calibrations were performed using fixed potential amperometry with a 
voltage of 0.7 V versus Ag/AgCl reference electrode in a beaker containing 
0.05M PBS solution which was constantly stirred and maintained at 37°C. Data 
was acquired at a rate of 5 Hz. After allowing 20 minutes for stabilization of 
background currents, aliquots of stock solutions of ascorbic acid (AA; 20 mM), 
choline (20 mM), and dopamine (DA; 2 mM) are added to the calibration beaker 
such that the final concentrations of the solutions are 250 µM AA, 20, 40, 60 and 
80 µM choline and 2 µM DA. The slope (sensitivity), linearity (R2) for choline, and 
selectivity ratio for AA and DA, were calculated for each individual recording site. 
The electrodes employed in the present experiments were characterized by a 
sensitivity for detecting choline: 7.34±1.84 pA/µM, a background current of <200 
pA, selectivity for choline:AA: 275.30 ±101.74, and a highly linear response to 
increasing choline concentrations (20-80 µM): R2: 0.997±0.001.  
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Figure 2.1 
Measurement scheme for choline electrochemistry.  Electrodes are implanted 
into the thalamic input layer of the prelimbic cortex. Newly released ACh is 
immediately hydrolyzed by acetylcholinesterase.  The enzymatic reaction 
between choline and choline oxidase results in the production of hydrogen 
peroxide, which is then oxidized by a fixed potential of 700 mV. This process 
releases electrons which are measured as increases in current.  The ability of 
this technique to measure changes in extracellular choline concentrations that 
are the result of newly released ACh has previously been validated (Parikh et al., 
2004).  
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Surgery and in vivo recording 
 
 Upon demonstration of task proficiency, animals were acclimated to the 
test chamber. They were trained daily in the new environment until they re-
established criterion level performance (approximately 2 weeks). After no less 
than three consecutive days of criterion level performance in the test chamber, 
animals were implanted with a CO-coated microelectrode. Surgeries were 
performed under aseptic conditions. Isoflurane (1-5%) was used to induce 
anesthesia (Anesco/Surgivet, Waukesha, WI). Anesthetized rats with shaved 
heads were placed in a stereotaxic frame (David Kopf, Model # 962, Tujunga, 
CA). Their body temperature was maintained at 37ºC using Deltaphase 
isothermal pad (Braintree Scientific, Braintree, MA).  
Following cessation of the pedal reflex, the scalp was cleansed with 
betadine. A ~10 mm incision was made along the midline. Three stainless steel 
screws were threaded in the cranium. Additional holes were drilled above the 
right prelimbic cortex and above a remote spot in the left hemisphere to 
accommodate the Ag/AgCl reference electrode. The microelectrode assembly 
was slowly lowered into the prelimbic region of the right mPFC (AP: +3.0 mm; ML: 
-0.7 mm, measured from Bregma; DV: -3.5 mm, measured from dura) using a 
microdrive (MO-10; Narishige, International, East Meadow, NY) and anchored to 
the skull with dental cement. Topical antibiotic (bacitracin, polymixin and 
neomycin) was applied to the wound immediately after surgery. All animals given 
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antibiotic (amikacin; 25 mg/kg; s.c.), an analgesic (buprenorphine, 0.01 mg/kg; 
s.c.), and saline (1.0 mL; i.p.) for two days post-operatively while remaining in 
their home cages with food and water ad libitum. After a 48-hour recovery period, 
the water restriction schedule was resumed. On a test day, the animal was 
placed in the chamber and the microelectrode assembly connected to the FAST-
16 system through a shielded cable, a low-impedance commutator, and a 
miniature headstage (mk-II RAT HAT; Quanteon, Lexington, KY). Recording 
sessions for the sustained attention task typically took place 3-5 days after 
surgery, allowing time for the animals to acclimate to the headstage. 
Amperometric recordings were collected every 500 ms (2 Hz) applying a fixed 
potential of 0.7 V to the microelectrode using the FAST-16 recording system. 
Data was captured using FAST-16 software. Amperometric recordings were 
time-locked by marking task events with TTL pulses. 
 
Bilateral prefrontal cholinergic deafferentation 
 
  SAT training procedures for this experiment were identical to those for the 
recording experiments. The final version of the task varied slightly, only in that 
task length was set to a fixed amount of time (40 minutes, approximately 200 
trials) as opposed to the number of trials.  Following acquisition of criterion level 
performance, animals (n=5) received bilateral lesions of PFC cholinergic inputs. 
Two infusions, one in mPFC and one in orbitofrontal cortex, of 192 IgG-saporin 
were administered per hemisphere with a 1 µL Hamilton syringe (100 ng/0.5 μL; 
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coordinates from bregma: AP: +3.0, +3.7; ML: ±0.7, ±2.0 mm; DV: -3.0, -3.7 mm).  
To maximize the spread, the toxin was delivered with a bolus infusion.  The 
needle was then left in place for 10 minutes to allow for diffusion. After recovering 
from surgery (1 week), animals were tested on the SAT for an additional 10 days.  
 
Quantifying extent of cholinergic deafferentation  
 
The extent of cholinergic dennervation in animals infused with the 
cholinotoxin was compared to non-performing animals (n=4) that were infused 
with a control toxin, saporin conjugated to the antibody for the mouse p75 
receptor, and used for histological comparison. Animals were transcardially 
perfused with ice-cold 0.1 M phosphate buffered saline followed by a 4% 
paraformaldehyde solution.  Brains were extracted, post-fixed for 24-hours, and 
then allowed to sit in 30% sucrose in phosphate buffered saline until they sunk.  
Brains were sliced in serial 40 µm sections on a freezing microtome (Leica 
Microsystems Inc, Bannockburn, IL).   
Acetylcholinesterase (AChE) positive fibers were visualized using a 
modified version of the protocol outlined by Tago et al. (Tago, Kimura, & Maeda, 
1986).  Free-floating sections were rinsed in 0.1 M phosphate buffer, and then 
incubated in 0.1% hydrogen peroxide for 30 minutes.  Sections were then rinsed 
in a 0.1M maleate buffer, and immersed in a 0.1 M sodium citrate, 5mM 
potassium ferracyanide, 30 mM cupric sulfate, and 30 mg of acetylthiocholine 
iodide in 0.1M maleate buffer.  Sections were then rinsed in a 30mM Tris buffer 
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and incubated in 3,3’ –diaminobenzidine with 0.75 mg of nickel ammonium 
sulfate per 250 ml of solution.  Approximately 200 µL of 3% hydrogen peroxide 
per 20 mL of solution was added after ten minutes and sections were allowed to 
incubate until cortical layering could be detected. Sections were then rinsed in a 
3mM Tris buffer and mounted on gel-coated slides.   
Verification of the extent of the lesions was accomplished by 
photographing sections at a magnification of 40X, and overlaying a 40 X 25 µm 
grid in Photoshop.  The number of AChE positive fibers making line crosses 
within a 4 X 4 square grid was quantified for two locations (one in mPFC and one 
from obitofrontal cortex) for each hemisphere from each animal.   
 
 Analysis of SAT Performance 
 
 In each session, the total number of Hits, Misses, correct rejections (CR), 
false alarms (FA), and omissions were recorded. Using these values, the relative 
number of Hits [h/(h+m)], correct rejections [cr/(fa+cr)], Misses (1-h), and FA (1-
cr) were determined.  
For the comparisons of the effect of bilateral prefrontal cholinergic 
deafferentation on SAT performance, data was lumped into four 3-day periods. 
The first period was the average performance over the 3 days immediately prior 
to surgery.  This measure served as a pre-manipulation baseline.  Because 
performance is uncharacteristically poor the first day on task after surgery, the 
data from this day was excluded from analyses of post-surgery performance.  
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Performance on days 2-4 post surgery was averaged together for the first post-
surgery time period, days 5-7 the next, and finally days 8-10.   
As detailed further below, the results of the electrochemistry experiments 
led us to hypothesize that the effects of prefrontal cholinergic deafferentation 
may manifest most robustly on performance on hit trials when the preceding trial 
was a CR or a Miss.  To quantify performance on such trials, joint probabilities, 
which reflect the probability of two events co-occurring, were calculated for each 
of the four possible sequences of hits. An example: to calculate the joint 
probability of a Hit following a CR, first the probability of a hit is determined 
[h/(h+m)].  Next the probability that a CR precedes a signal trial is calculated 
[(#CR preceding signal trials/total #CR)]. Employing the multiplicative law, the 
joint probability was determined by calculating the product of these two terms 
(Howell, 1989). 
 
Electrochemical signal processing 
 
 Current recordings from each platinum site were normalized by dividing 
the raw current value at each time point by the change in current following the 
addition of DA observed on that site during calibration. The normalized currents 
recorded from the non-CO coated sites were then subtracted from the 
normalized currents recorded at the CO-coated sites (“self-referencing”). These 
subtracted values were then converted to approximations of extracellular choline 
by dividing by the sensitivity of the CO-coated electrode determined in calibration. 
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Trial by trial analysis of electrochemical data 
  
Data was organized in 0.5 s time bins, and normalized to the data point 5 
seconds prior to the signal or non signal event (e.g. 7 s prior to lever extension) 
by setting this point equal to 0 and every point after the difference from this value. 
The choline concentrations for each data point over the 2 s prior to the onset of 
the signal (or the analogous time period on a non-signal trial) were averaged 
together and served as the pre-trial baseline. Because we were interested in 
changes in cholinergic activity proximal to cue and lever extension only the 4 s 
after the signal were used for statistical analysis.  To reiterate, there is a two 
second delay between cue and lever extension on a signal trial, thus this time 
window includes a 2 s time window following signal and lever extension.  
Absolute changes in extracellular choline levels reported in the results are the 
difference between peak choline concentration value and the pre-cue baseline 
period.  A total of 191 Hits, 236 CR, and 102 Misses were included in the final 
analyses.  False alarms occurred only rarely (9.88% of all trials recorded). 
Because of the low number of such trials they were not included in the analyses.    
 
Statistical analysis 
  
 Hits during SAT performance were analyzed with repeated-measures 
ANOVAs with the factors of signal duration and block of performance. CR and 
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the percent of omitted trials were analyzed with one-way repeated measures 
ANOVA with a factor of Block. The electrochemical data were analyzed repeated 
measures ANOVAs with a factor of time (Baseline, followed by the 4 seconds 
post cue).   A significant change in extracellular choline levels relative to baseline 
would be indicated by a main effect of time.  
The consequences of removal of prefrontal cholinergic inputs on 
performance in the SAT were analyzed with repeated measures ANOVA with an 
additional factor of day (baseline, Day 2-4, Day 5-7, Day 8-10). Joint probabilities 
were calculated for each hit sequence (across signal duration).  Any significant 
alterations in performance, relative to baseline, are indicated by a main effect of 
Day.           
 Results of all statistical tests are reported with Huyhn-Feldt corrected 
values.  All post hoc analyses employed the least significant difference test (LSD). 
When warranted, main effects, interactions, and exploratory analyses were 
carried out with paired samples t-tests (α=0.05).  
 
Results 
SAT Performance during electrochemistry 
  
 Animals’ performance in the SAT during recording sessions is 
summarized in Figure 2.2.  The percentage of signal trials resulting in hits was 
signal duration dependent (F(2,8)=27.32; p<0.001) with the percentage of 
detected trials declining with shorter signal durations. Animals correctly rejected 
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79.06±5.09% of non-signal events.  Animals also omitted very few trials 
(4.44±2.96% of trials/session).  Finally, performance did not vary across blocks of 
task performance for any measure (all p’s >0.20).  Response latencies (time 
between lever extension and press) followed a fairly predictable pattern with the 
fastest responses on hits (640.51±34.57 ms, recall the animal has detected the 
cue and can begin preparing to respond prior to lever extension) and consistent 
across all other trial types, always taking less than one second (overall mean: 
844.43 ± 13.76 ms).  
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Figure 2.2 
Performance during choline electrochemistry experiments (Y axis; % of correct 
trials, X axis: Block of trials; M;SEM).  Performance on signal trials (A) was signal 
duration dependent, and animals correctly rejected (B) the majority on non-signal 
trials.  Performance on both trial types did not vary across the time spent on task.  
The number of omitted trials was low (4.44±2.96%) and response latencies were 
less than one second for all trial types (overall mean 844.43 ± 13.76 ms). 
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Cholinergic activity during SAT performance 
  
 As predicted detected cues, or hits, were associated with an increase in 
extracellular choline levels that began following the presentation of the cue and 
prior the extension of the lever (main effect of time; (F( 9, 1710) = 7.21, p<0.001). 
Levels of extracellular choline were significantly elevated relative to baseline by 
the time of lever extension (2 s post cue; p=0.002), and continued to rise to 
130.43 ± 30.57 nM above baseline at 4 s post cue (Figure 2.3a). As is clear from 
Figure 2.3a, extracellular choline levels continued to rise even beyond the 4 s 
time point, eventually peaking 163.31 ± 31.19 nM above baseline 6.5 s post-
signal. On signal trials that resulted in a Miss, there was no significant change in 
extracellular choline levels following the presentation of the cue or across the 4 s 
time window relative to baseline (F(9,909)=1.70, p=0.137).  On trials resulting in 
a correct rejection (Figure 2.3b), there was no increase in extracellular choline 
concentrations (F(9,2106)=2.51, p=0.012). Levels actually declined and reached 
a low point 1 s after lever extension (-79.10 ± 28.05 nM, p=0.005).   
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Figure 2.3 
In agreement with previous studies suggesting that increases in cholinergic 
activity mediate cue detection, levels of extracellular choline began to increase 
following the cue on hit trials (A).  Correct rejections, which also include a lever 
press, reward presentation, and retrieval, were not associated with such 
increases and actually tended to decrease (B). 
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Variability in cholinergic activity on hits  
 
 An interesting caveat of the data described above is that increases in 
cholinergic activity were only seen ~3/5 (60.69%) of hits analyzed. Two 
exploratory analyses were carried out to attempt to account for this variability.  
The first examined the change in choline concentrations on hits as a function of 
signal duration. As expected, the number of Hit trials available for analysis 
differed by signal duration, so a random subset of Hits to 500ms and 50ms 
signals was selected for comparison with hits to 25 ms signal.  There was no 
evidence that extracellular choline concentrations varied as a function of signal 
duration (Main effect of signal duration: F(2,86)=0.44, p=0.636).  Next, Hit trials 
were classified and separated by the response on the previous trial.  When the 
data was parsed in this way a pattern began to emerge.  As illustrated in Figure 
2.4 if the hit was preceded by a CR (2.4b) or Miss (2.4c), there was an increase 
in cholinergic activity following the presentation of the cue. In contrast, if the hit 
was preceded by another hit trial, cue detection did not evoke a change in 
extracellular choline levels on the second Hit trial of the sequence.  The number 
of hits of each trial sequence type differed, the fewest number being 32 for 
MissHit sequences.  32 CRHit and 32 HitHit sequences were randomly 
selected, and compared with 2-way repeated measures ANOVA with the factors 
of time and sequence. Extracellular choline levels varied across the 4 s time 
window as a function of the previous trial (time X sequence interaction; F(18,558) 
= 3.06, p=0.002).  There was no difference in the pre-trial baseline levels of 
extracellular choline between trial sequences (F(2,62)=.291, p=0.737).  Further 
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analyses of changes in choline levels were done within individual trial sequences. 
For CRHit sequences, there was a significant increase in cholinergic activity 
(F(9,801)=5.91, p<0.001). Extracellular levels began increasing after the 
termination of the cue, reaching levels above baseline by the time the lever was 
extended (p=0.022), and continued to rise throughout the next 2 s (Figure 2.4b, 
peak of increase at 4 s: 151.00 ± 41.45 nM). The rise in current levels continued 
past the 4 s time point, peaking at 212.13 ± 42.29 nM above baseline at 6.5 s 
post signal.  There was also a significant increase in cholinergic activity on 
MissHit trials (F(9,279)=4.18, p=0.002). Like CRHit trials, extracellular 
choline levels began to rise following the presentation of the cue.  The pattern of 
change did differ slightly, with the increase in extracellular choline reaching 
significance by 1.5 s post cue (LSD p=0.004), however the overall trend was the 
same with levels increasing throughout the remainder of the 4 s period (peak 
change from baseline at 4 s: 282.43 ± 88.1 nM) and beyond. By 6.5 s post signal, 
levels had reached 368.70 ± 95.31 nM above baseline. In contrast, on a 2 hit 
sequence (HitHit), extracellular choline levels did not change over the 4 s 
window (F(9,612)=1.599, p=0.181). The overall increase in extracellular choline 
levels appeared greater on MissHit sequences than on CRHit, however the 
two sequences did not differ in a comparison using the same randomly selected 
trials above, even if the analysis included the entire 11 s post cue (main effect of 
sequence and sequence X time interaction, both p’s >0.23).   
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Figure 2.4 
 
In contrast to our preliminary hypothesis, not all detected cues evoked increases 
in cholinergic activity.  Whether a Hit was associated with significant increase in 
extracellular choline levels was dependent upon the previous trial type.  Hit trials 
preceded by a CR or Miss evoked an increase (A and B), while on HitHit 
sequences signal presentation and detection did not evoke an increase. 
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Effect of bilateral prefrontal cholinergic deafferentation 
 
The extent of cholinergic deafferentation is presented in Figure 2.5.  All 
animals received infusions of the cholinotoxin in both the mPFC and the 
orbitofrontal cortex. Compared to controls, there was a modest reduction (41.4 
±7.2%) of AChE positive fibers in the mPFC (2.5a, 2.5b).  The extent of fiber 
reduction was more robust (80.50 ± 3.62%) in the oribitofrontal portion of the 
PFC (2.5c, 2.5d).  The reason for the discrepancy in the effectiveness of the toxin 
in the two different regions is unknown, but as will be described below, the limited 
effects on performance following the lesion may be attributable to the lack of 
deafferentation in the mPFC. Preliminary behavioral results are illustrated in 
Figure 2.6.  Bilateral prefrontal cholinergic deafferentation had limited impacts 
performance on the SAT, although the pattern of results is consistent with the 
electrochemical data.    Performance on non-signal trials was not impaired 
(Figure 2.6b, effect of Day; F(3,12)=1.32, p=0.32), and the proportion of omitted 
trials did not significantly increase (Day; F(3,12)= 2.78, p=0.15). The number of 
hits (irrespective of sequence) did not differ significantly from baseline (effect of 
Day; F(3,12)=1.84, p=0.199). Although the statistical test did not reach 
significance, as illustrated in Figure 2.6a there was a trend towards reduced 
numbers of detected trials, most evident at the middle, 50 ms signal duration, 
reaching its lowest point between days 5-7 post surgery (paired-t test comparing 
50 ms hits at baseline and days 5-7; (t(4)=2.81, p=0.049)).   Thus it seems 
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possible that the lack of effects in the omnibus test was due to the relatively small 
n, lesion, and a lack of statistical power.   
 Subsequent analyses explored the effect of prefrontal cholinergic 
deafferentation on performance on hit sequences.  Joint probabilities were 
calculated as described above for each of the 3 possible hit contingencies 
(CRHit, MissHit, HitHit).  Relative to baseline, the probability for a Hit 
following a Miss was significantly reduced (Figure 2.6c, Main effect of Day 
F(3,12)=5.13, p=0.030).  This decrease was most robust over Days 2-4 (LSD, 
p=0.048), and although performance did not fully recover, additional pairwise 
comparisons were not significant for Days 5-7 or 8-10.  The probability for a hit 
on all other sequences was not significantly affected by cholinergic 
deafferentation (all p’s >0.180). 
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Figure 2.5 
Representative images of the extent of cholinergic deafferentation in the mPFC 
and orbitofrontal cortex.  The black dots on the coronal sections indicate the 
location the image was taken from. The toxin modestly reduced the number of 
AChE positive fibers in the more anterior, prelimbic regions (A control,C lesion). 
The toxin had a more profound effect on fiber density in orbitofrontal areas (B 
control, D lesion).  
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Figure 2.6 
SAT performance following bilateral, prefrontal cholinergic deafferentation.  
Performance on signal trials was moderately impaired (A). Performance on non 
signal trials did not differ, relative to pre-surgery levels, following removal of 
prefrontal cholinergic inputs (B).  Joint probability analyses support the 
proposition that cue detection was particularly impaired on trials involving a non-
signal-to-signal shift, as reflected by a reduced probability for a Hit following a 
Miss (C) 
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Discussion 
Prefrontal cholinergic transients in SAT-performing rats  
 Based upon the effects of selective removal of cholinergic inputs to the 
cortex, and preliminary experiments employing choline sensitive microelectrodes 
in animals performing a cued appetitive response task (McGaughy, et al., 1996; 
Parikh, et al., 2007), we hypothesized that detected cues on Hits evoke 
increases in cholinergic neurotransmission in prefrontal regions, and removal of 
prefrontal cholinergic inputs would impair Hit performance. In the present study, 
only Hits were associated with increases in cholinergic activity. However in 
contrast to our initial hypothesis, such increases were only seen when the Hit 
was preceded by a CR or Miss. In addition, bilateral removal of prefrontal 
cholinergic inputs selectively impaired performance on MissHit trial sequences, 
while performance on other Hit sequences was spared.  Because of the trial 
sequence-dependent occurrence of increases in cholinergic activity in hit trials, 
and the selective performance impairment, our relatively straightforward 
hypothesis about the role of these increases in cue detection must be revisited.   
At present, we have focused on two different possible explanations of the 
selectivity of cholinergic activity in the SAT, each of which places emphasis upon 
different parts of the cholinergic release event.  The first focuses solely upon the 
trial sequence dependence of an evoked cholinergic signal, and particular 
attention is paid to the fact that levels of cholinergic activity are significantly 
elevated at the time the animals are prompted to make their response. The 
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functional relevance of the remainder of the signal is not considered. The second 
explanation attempts to account for the sequence dependency, as well as the full 
time course of the release, the major assumption being that as choline levels 
continue to increase, ACh release and hydrolyzation must be ongoing.  Future 
experiments designed to test both of these possibilities will be addressed in the 
General Discussion.  
Cue-evoked increases in cholinergic activity mediate the shift between cue 
independent to cue dependent attention 
 Cholinergic activity begins to rise following the offset of the cue during hit 
trials if preceded by a non signal trial response (CR or Miss), reaching levels 
significantly above baseline at the time of lever extension when the animal must 
then indicate the presence or absence of the signal.  It has been proposed that in 
order for a cue to be detected (as defined by Posner, see above), the afferent 
(presumably mediodorsal thalamic, discussed further in Chapter III) 
representation of the cue must be allowed to be integrated into ongoing 
processing so that it can be used to guide responding (Hasselmo & Sarter, 2010).  
In the cortex, stimulation of muscarinic receptors can suppress intracortical 
inputs, while afferent input is unaffected (Hasselmo & Bower, 1992).  To extend 
this neurophysiological finding to performance in the SAT, non-signal trial 
responding does not require cue detection and therefore responses are based 
primarily upon intracortical or associational processing. By suppressing synaptic 
communication between cortical structures, a cholinergic release event could 
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function to effectively suppress interfering or competing activity and allow the 
representation of the cue to inform action selection. 
  An extension of this theory is that the transition from non-signal to signal 
based attentional processing requires that the state of PFC circuitry be shifted 
from one dominated by intracortical inputs (cue-independent processing) to one 
that facilitates the utilization of external, predictive cues (cue-dependent 
processing).  A cholinergic transient need not be generated by every detected 
cue, as if the previous trial was a detected signal trial, then the state of the 
network would have already been shifted.   
 Shifts from cue-independent to cue-dependent processing are associated 
with significant right PFC (Broadman’s area 10) activation in human imaging 
studies (Burgess, et al., 2007). Interestingly, a recent study in humans 
performing a reverse-engineered version of the SAT demonstrated that Hits on 
such non-signalsignal sequences evoke greater right PFC activation in 
Broadman’s area 10 than on signalsignal Hit sequences  (Lustig, 2011). Thus, 
the data described here may be indicative of a transient increase in cholinergic 
activity underlying the shift from cue-independent to cue-dependent processing 
modes.   
Increases in cholinergic activity as a learning signal 
 Although the increase cholinergic activity began early in the trial, it 
continued to increase well beyond this time point, peaking at around 6.5 s post-
cue. Thus, cue-evoked cholinergic transients during hits in incongruent trial 
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sequences may have another function beyond attention mode shifts and cue 
detection, perhaps acting as a reporter or learning signal.  ACh can increase the 
strength of the relationship between cue and response by augmenting long-term 
potentiation in both the hippocampus and cortex, effectively lowering the 
stimulation threshold for inducing an increase in synaptic strength (Hasselmo & 
Barkai, 1995; Huerta & Lisman, 1993).  Stimulation of basal forebrain cholinergic 
projections have been shown to enhance the cortical coding of a sensory 
stimulus (Goard & Dan, 2009; Metherate & Ashe, 1991, 1993), which has been 
suggested to both aid in the formation and later support association between a 
conditioned and unconditioned stimulus (Weinberger, 2003).     
 In the context of animals performing the sustained attention task, the 
learning signal may serve to stabilize or increase the readiness for shifting from 
cue-independent to cue-oriented attention and refresh the processing of the 
response rule for cues (e.g., “if signal press left lever”). During successive hits, 
no second or third learning signals are generated. Thus, a prior correct rejection 
or a miss, or prior cue-independent attention, and the shift to cue-oriented 
attention are conditions for generating this learning signal.  
Reconciling past results      
 Whether cholinergic transients selectively mediate the transition from cue 
dependent to cue independent processing, or also reflect a reporter or learning 
signal that strengthens cueresponsereward associations, both afford 
alternative interpretations of the previous study with the cued-appetitive response 
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task (Parikh, et al., 2007). The long ITI (90±30 s) cued-appetitive task fostered 
engagement in cue-independent behavior (e.g. grooming). Therefore, if the first 
speculation is correct, every detected cue evoked a cholinergic transient because 
the animal shifted from cue-dependent to cue-independent behavior during the 
ITI.           
 If cholinergic transients act as a learning signal, they would not be 
predicted to be evoked by reward delivery, even though they act as a cue for 
reward port approach in miss trials. This behavior is unrelated to strengthening 
the association between a predictive cue and reward. It’s also intriguing to 
consider the results of additional experiments conducted by Parikh and 
colleagues. In the first series, the interval between cue and reward delivery was 
varied (either 6 or 2 s post cue).  In either case, the cholinergic transient peaked 
at the time of reward delivery. This observation is consistent with the hypothesis 
that cholinergic activity “confirms” or reinforces an incongruent detection 
requiring reward delivery as the final step. Further, in trials in which the cue was 
detected but reward was not delivered, the amplitude of cholinergic transients 
were attenuated and peaked within 3 s after the cue (cue-reward period was 6±2 
s). This data could be interpreted as indicating that in the absence of reward, 
detection confirmation collapsed, and as a consequence blocked the learning 
signal. Together, both seem consistent with the second hypothesis that delivery 
strengthens the association between cue and reward. It is important to reiterate 
that reward per se does not elicit cholinergic activity, as indicated by the absence 
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of cholinergic transients during rewarded misses in the former study or during 
successive hits and CR in SAT-performing animals. 
Effects of prefrontal cholinergic lesions  
 We chose to target the prelimbic and orbitofrontal cortices for cholinergic 
deafferentation because of where we observe cholinergic transients (prelimbic), 
and based upon the recent replication of the sequence dependent increases in 
activation on hits in humans performing the SAT (an anatomical analogue of 
Broadmann’s area 10 does not exist in rats, although it was our speculation that 
the rodent orbitofrontal cortex would be the closest functional homologue).   
Cholinergic deafferentation of these two areas was not sufficient to impair 
performance on all Hit sequences associated with increases in cholinergic 
activity.  The lack of robust effects could be attributed to the extent of the lesion 
in prelimbic areas being limited (~40%).  However, it could also be the case that 
there exists a distributed network of cortical areas where cholinergic input is an 
important contributor that were not targeted.  For example, the posterior parietal 
cortex is a prominent feature in many models of attentional networks (Corbetta, 
et al., 2000; Shulman, d'Avossa, Tansy, & Corbetta, 2002). Cholinergic inputs to 
this area modulate cue evoked neural activity on Hits in animals performing the 
SAT (Broussard, Karelina, Sarter, & Givens, 2009) and are necessary for the 
performance enhancing effects of nucleus accumbens shell stimulation in 
animals performing a version of the task that includes a distracting stimulus (St 
Peters, et al., 2011).   Thus a more extensive cholinergic lesion is likely 
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necessary to create a robust impairment in performance on CRHit and 
MissHit trials.            
 The effects of the lesion in this study did however follow an interesting 
pattern. The difference in the amplitude of cholinergic activity on CRHit and 
MissHit sequences was not statistically significant.  Inspection of Figure 2.4 
however, indicates a trend towards a greater increase in extracellular choline on 
a MissHit sequence.  Further analyses and perhaps the addition of just 1-2 
animals to the data set may bare this difference out, and indicate larger 
amplitudes of cholinergic transients for Hits after a Miss when compared with hits 
after a correct rejection.  Such a finding could be interpreted as indicating that 
cue-independent attention in the SAT is enforced by detection failures (misses), 
and a larger transient is needed to drive a shift or, a larger learning signal is 
generated to reinforce the response rules.  If such transitions require a greater 
increase in prefrontal cholinergic neurotransmission, this could explain why even 
a limited lesion such as the one in this study could impair performance on these 
trials.        
Implications for pre-clinical research 
Here we report that cue evoked, transient increases in ACh release mediate not 
signal detection as previously hypothesized, but specifically when a transition 
from cue-independent to cue-dependent processing is required. Given the 
hypothesized role of cholinergic dysregulation in the cognitive impairments 
associated with psychopathology it is not surprising that many cholinomimetic 
  57 
drugs have developed as potential treatments. However, with the exception of 
selective agonists of α4β2 nicotinic receptors which have shown promise, few 
have been clinically effective  (Bartus, et al., 1982; Deutsch, 1971; Everitt & 
Robbins, 1997; Freedman, et al., 2008; Sarter, 2006; Sarter, Parikh, et al., 2009). 
This lack of efficacy is likely due to misconceptions regarding the role of the 
cholinergic system in cognitive performance. By helping to define the precise 
cognitive operations under cholinergic control and more specifically, how 
cholinergic systems orchestrate these functions, the present research will 
hopefully help to guide the development of pharmacotherapies towards a more 
productive future. 
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Chapter III 
 
Prefrontal glutamatergic signaling during attentional performance: 
relationship to cholinergic activity 
 
Summary 
 
 Mounting evidence suggests prefrontal cholinergic-glutamatergic 
interactions mediate attentional processes and capacities. Transient increases in 
medial prefrontal (mPFC) cholinergic activity (scale of seconds) mediate the shift 
between cue-independent and cue-dependent attentional processing. Previous 
work in anesthetized preparations suggests that the generation of cholinergic 
transients depends in part on the stimulation of ionotropic glutamate receptors by 
glutamate released from mediodorsal thalamic afferents (Parikh, et al., 2010; 
Parikh, et al., 2007; Parikh, et al., 2008). The present experiments measured 
real-time glutamate release in the thalamic input layer of the mPFC in animals 
performing a sustained attention task (SAT). We hypothesized that on signal 
trials resulting in a Hit, the cue would evoked glutamate release. The rise and 
peak of this glutamate release will, on average, precede that observed on 
cholinergic transients.  As Hit rates are signal duration dependent, the amplitude 
of cue-evoked glutamate release would vary as a function of signal duration. 
Tonic cholinergic activity (scale of minutes) functions to support the control of 
attention. Mediodorsal thalamic projections to the mPFC express α4β2 nicotinic 
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receptors presynaptically, and thus can themselves be modulated by such tonic 
cholinergic activity.  We hypothesized that the amplitude of glutamatergic 
transients would be larger during periods of good performance (when tonic levels 
would be elevated) than in periods of poor performance.   Correct rejections and 
Misses will not be associated with increases in glutamate release.  In agreement 
with our hypothesis, the cue on signal trials resulting in Hits evoked an increase 
in glutamate release.  The amplitude of this cue-evoked release was signal 
duration dependent.  Further, the glutamatergic transients on Hits during periods 
of good performance were characterized by larger amplitudes than Hits during 
poor performance.  In contrast to our hypotheses, lever extension on both CR 
and Misses also evoked glutamate release.  The presence of glutamatergic 
transients at lever extension on CR and Misses suggests that in addition to 
supporting the generation of cholinergic transients, gluatmatergic transients may 
also represent the detection of any stimulus that prompts a decision or choice 
and the initiation of a response.   
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Introduction 
 
 Attentional functions and capacities are central to cognitive performance. 
The cortical cholinergic input system is a necessary component of the neural 
circuitry of attention (Everitt & Robbins, 1997; McGaughy, et al., 2002; 
McGaughy, et al., 1999; McGaughy, et al., 1996; Sarter, et al., 2005). We have 
recently shown that transient increases in cholinergic activity in the medial 
prefrontal cortex (mPFC) mediate the ability to shift from cue independent to cue 
dependent attentional processing, and may also serve as a learning or reporter 
signal to reinforce the ability to engage in such shifts (Hasselmo & Sarter, 2010; 
Parikh, et al., 2007; Sarter, Parikh, et al., 2009). Mechanistic studies of the 
mPFC circuitry underlying the generation of these cholinergic transients have 
revealed that they are a product of local cholinergic-glutamatergic interactions.  
They require glutamate release and the stimulation of ionotropic glutamate 
receptors located on cholinergic terminals (Parikh, et al., 2008). Such glutamate 
release originates from projections from the mediodorsal thalamic nucleus 
(Parikh, et al., 2010).  These thalamic inputs are hypothesized to act as an 
extension of the thalamic reticular nucleus “attentional searchlight” (Crick, 1984),  
and help recruit attentional mechanisms by importing information about a 
predictive cue to prefrontal networks, in turn engaging mPFC cholinergic 
mechanisms, and ultimately generating cholinergic transients.  
We have developed a model of a prefrontal network illustrating such 
glutamatergic-cholinergic interactions in attentional performance (see Figure 3.1).  
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An important aspect of the model concerns the presence of two modes of 
cholinergic neurotransmission (Hasselmo & Sarter, 2010; Parikh, et al., 2007).  In 
addition to transient or brief increases in ACh release, there is a tonically active 
mode of cholinergic activity that changes on the scale of tens of seconds to 
minutes.  Current evidence suggests that levels of tonic cholinergic activity are 
mediated by prefrontal-nucleus accumbens-basal forebrain interactions, and 
function to support the control of attention (Sarter & Paolone, 2011; St Peters, et 
al., 2011). For example, engagement in and performance of tasks taxing  
attentional capacities, but not tasks designed to control for locomotor activity and 
reward presentation, evoke tonic increases in ACh release (Arnold, et al., 2002). 
Further, tonic cholinergic activity is increased in the face of enhanced demands 
on attentional control, such as those imposed by disruption of prefrontal 
cholinergic neurotransmission, attentional fatigue, or a distracting stimulus 
(Kozak, et al., 2006; Sarter, et al., 2006; Sarter & Paolone, 2011; St Peters, et al., 
2011). Thalamic afferents to the mPFC express α4β2 nicotinic acetylcholine 
receptors (nAChRs) (Dickinson, et al., 2008; Lambe, et al., 2003). The current 
model speculates that tonic cholinergic activity modulates glutamate release from 
mediodorsal thalamic afferents via 42* nicotinic acetylcholine receptors 
(nAChRs). These receptors are situated on the terminals of the thalamic input 
(Purple projection from BF in figure 3.1 (Lambe, et al., 2003; Parikh, et al., 2010; 
Parikh, et al., 2008), and thus support attentional performance by dictating the 
likelihood of a cholinergic transient.   
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Although the current evidence largely supports the model depicted in 
Figure 3.1, the initial experiments that informed the function and circuitry of this 
mPFC attention network utilized either relatively simple instrumental tasks or 
anesthetized preparations, prohibiting efforts to directly demonstrate how 
cholinergic and glutamatergic mechanisms might interact to mediate attentional 
performance. In the present experiments glutamate release was measured on a 
sub-second time scale in the thalamic input layer of the mPFC of animals 
performing a sustained attention task (SAT).  We tested hypotheses that 1) in an 
operant test of sustained attention which includes the complexity of both signal 
and non-signal trials, detected signals evoke glutamatergic transients 2) as 
glutamate and stimulation of ionotropic receptors stimulate cholinergic transients, 
the onset and peak of glutamatergic transients will precede cholinergic transients. 
3) Performance on signal trials in the SAT is signal duration dependent, and 
glutamate release appears to determine the likelihood of generating a cholinergic 
transient, therefore the amplitude of cue evoked glutamate release will also vary 
as a function of signal duration 4) trials resulting in a Miss will be associated with 
a smaller or undetectable glutamate release event than those measured on Hits 
5) responses on non-signal trials will not be associated with any significant 
change in glutamatergic activity.  A final exploratory analysis was conducted to 
assess the potential role of tonic modulation of prefrontal glutamatergic signaling.  
The characteristics of cue-evoked glutamatergic activity on Hits during periods of 
good performance (when tonic levels of cholinergic activity would be 
hypothesized to augmented) was compared to periods of poor performance 
  73 
(when performance hovers around chance levels, reflecting a lack of attentional 
control and thus tonic release would be relatively lower). 
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Figure 3.1 
Hypothesized model of mPFC circuitry underlying cholinergic transients and 
associated attentional performance.  Cholinergic transients are the product of 
glutamate release from mediodorsal thalamic afferents (blue input) stimulating 
ionotropic (AMPA/NMDA) receptors situated on the terminals of cholinergic 
inputs (red input).  A second, tonic, mode of cholinergic activity (purple input) 
modulates the amplitude of cue-evoked glutamate release by actions at α4β2 
nAChRs, thereby controlling the probability of evoking a cholinergic transient and 
a successful shift between cue independent and cue dependent attention. Figure 
taken from Hasselmo & Sarter, 2010  
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MATERIALS AND METHODS 
Subjects 
  
 Subjects (n=3) were male Wistar rats approximately 60 days old (200-
300g) at the onset of training. Animals were kept on a 14:10 light/dark cycle in a 
temperature and humidity-controlled vivarium. Water was only available as a 
reward during testing and for 30 min upon the completion of the training/testing 
session. Food was available ad libitum. All training and testing took place during 
the light cycle between 0800-1700 hours. Animals were maintained in 
accordance with the NIH guide for the Care and Use of Animals and experiments 
were conducted in accordance with protocols approved by the University of 
Michigan Committee on Use and Care of Animals (UCUCA).         
 
Apparatus 
 
 Rats were trained in one of twelve operant chambers (Med Associates, 
Georgia, Vt., USA) enclosed within a sound attenuating box and equipped with a 
fan to conceal any residual background noise. Each chamber was equipped with 
a water port located between two retractable levers. A central panel light was 
located at the front of each chamber above the water port. Additional panel lights 
were located above each lever. A house light was positioned at the back of the 
chamber. All training and testing programs were executed with a PC running 
Med-PC software (V. IV).  
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 Electrochemical recordings were conducted in a 12” X 10” X 17” wooden 
operant chamber completely shielded by copper-wire mesh and equipped with 
two retractable levers constructed of fiberboard normally employed for electrical 
insulation. The receptacle used for water delivery was constructed from copper. 
The entire assembly was connected to an electrical ground. The relative location 
of the central panel light is the same as in the training chambers. The 
background illumination provided by the houselight, and the change in luminance 
following the presentation of the signal were kept constant between training and 
testing environments. 
 
Pre-surgical training procedures 
 
 Animals were trained in the same chamber daily, and a  houselight located 
at the back of the chamber is illuminated throughout training/test sessions.  In the 
first stage of training the two response levers were extended into the operant 
chamber and remained so throughout the session. A press on either lever led to 
access to 0.1 mL of water (FR-1 schedule), with the rule that if, for example, at 
any time the number of presses on the left lever was 5 greater than the number 
of presses on the right, the left lever becomes inactive until the right lever is 
pressed. This rule was designed to discourage the development of a lever or side 
bias. This phase of training continued until animals reached the criterion of 120 
rewards per session (approximately 45 min) for two consecutive days.  
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In the second stage of training, animals had to discriminate between 
signal (illumination of central panel light) and non-signal (no illumination of 
central panel light) trials. It is important to note that the houselight prevents 
animals from being able to monitor for simple changes in chamber brightness, 
and must direct their focus to the intelligence panel for above chance 
performance.  Each session included 160 trials equally divided between signal 
and non-signal. Correct responses were rewarded with water. On a signal trial, 
the signal light was turned for 1 second. Two seconds later the response levers 
were extended into the chamber. A press on the left lever was considered correct, 
and scored as a hit. A press on the right lever was scored as a miss. On non-
signal trials, a press on the right lever was considered correct, and the trial 
scored as a correct rejection. A press of the left lever was considered incorrect, 
and scored as a false alarm (note: half of all animals were trained with non-signal 
and signal response levers in the reverse position). The levers were retracted 
after being depressed regardless of whether the response was correct or 
incorrect. An omission was reported when animals failed to press either lever 
after four seconds, at which time both levers were retracted. Incorrect responses 
were followed by correction trials identical to the previous trial. After three 
consecutive errors on correction trials, animals were given a forced choice trial. If 
the error had occurred on a signal trial, the left lever alone was extended while 
the central panel light and the light directly above the correct lever remain 
illuminated. Only the right lever is extended into the chamber in the case of a 
non-signal trial.  The inter trial interval (lTI) was 12±3 s during this stage of 
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training. Performance criterion for this stage was >70% hits and correct rejections 
for three consecutive sessions.  
In the third stage of training the correction and forced trials were dropped, 
and the ITI was decreased to 9±3 s. The signal duration remained fixed at 1 s 
and sessions consisted of a total of 162 trials. As with the previous stage, 
criterion for advancement was >70% hits and correct rejections for three 
consecutive sessions. 
In the final version of the task, signal duration was shortened and varied 
(500, 50, or 25 ms). Training sessions were timed to last 40 minutes with a total 
of ~200 trials, half signal and half non-signal. Performance was analyzed in 5 
blocks of trials, each 8 minutes in duration. Signal and non-signal trials were 
presented in a pseudo-randomized order. Animals were trained on the final 
version of the task until performance reached a plateau. Only animals with >70% 
hits to 500 ms signals and >70% correct rejections were employed in the present 
experiments.  
 
Preparation and Calibration of Enzyme-Selective Microelectrodes  
 
Multi-site microelectrodes were purchased from the Center for 
Microelectrode Technology at the University of Kentucky (Quanteon LLC, 
Nicholasville, KY; see Fig. 1A).  Each electrode array featured four 15x333 m 
Platinum-recording sites arranged in side-by-side pairs. The pairs of electrodes 
were separated by 100 µm, and 30 µm separated sites in a pair.  Connecting 
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lines and recording sites were imprinted on a ceramic base ~ 125 µm thick. The 
connecting lines were coated with a layer of polyamide for insulation. The entire 
assembly was connected to circuit board. Microelectrodes were modified for 
recordings in freely moving animals by soldering four 2 cm pieces of enamel-
coated magnet wire (30 ga) to gold terminals on the circuit board, each of which 
was connected to an individual recording site. The other end of the wire was 
connected to a female gold-pin. The gold-pins were inserted into a miniature 9-
pin connector and glued to the microelectrode assembly using epoxy. The 
Ag/AgCl reference electrodes were constructed of 0.008” diameter silver wire (A-
M Systems, Carlsberg, WA) soldered to a gold-pin, which was also inserted into 
the connector.  
After assembly, electrodes were dip-coated with Nafion™ and then baked 
at 170°C for 4 minutes to repel anionic interferents from the platinum sites.  The 
bottom pair of recording sites were then coated with glutamate oxidase (GO) that 
had been cross-linked with a bovine serum-albumin (BSA)-glutaraldehyde 
mixture (1% GO, 1% BSA and 0.125% glutaraldehyde) using a 1µL syringe 
(Hamilton, Reno, NV, USA). The remaining two recording sites were coated with 
the BSA-glutaraldehyde solution alone and served to record background activity. 
Enzyme-coated microelectrodes were allowed to cure of 48-72 hrs in a 
desiccator prior to calibration (See Figure 3.2 for illustration of measurement 
scheme.  
Calibrations were performed using fixed potential amperometry with a 
voltage of 0.7 V versus Ag/AgCl reference electrode in a beaker containing 
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0.05M PBS solution which was constantly stirred and maintained at 37°C. Data 
was acquired at a rate of 5 Hz. After allowing 20 minutes for stabilization of 
background currents, aliquots of stock solutions of ascorbic acid (AA; 20 mM), 
glutamate (20 mM), and dopamine (DA; 2 mM) are added to the calibration 
beaker such that the final concentrations of the solutions are 250 µM AA, 20, 40, 
60 and 80 µM glutamate and 2 µM DA. The slope (sensitivity), linearity (R2) for 
glutamate, as well as selectivity ratio for AA and DA, are calculated for each 
individual recording site and recordings from GO-coated sites were self-
referenced. The electrodes employed in these experiments were characterized 
by a sensitivity for detecting glutamate of 7.57±0.81 pA/µM, a background current 
of <200 pA, a selectivity for glutamate:AA: of 379.74±285.41, and a highly linear 
response to increasing glutamate concentrations (20-80 µM): R2=0.95± 0.04. 
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Figure 3.2 
 
Measurement scheme for glutamate electrochemistry.  Platinum recording 
electrodes are dip coated with nafion to repel anionic interferents (such as 
ascorbic acid). Glutamate oxidase is immobilized on the platinum surface with a 
BSA-glutaraldehyde protein matrix. Extra-synaptic glutamate comes in to contact 
with glutamate oxidase, resulting in the production of α-ketoglutarate and 
hydrogen peroxide.  This hydrogen peroxide is oxidized by the fixed potential of 
700 mv, releasing electrons that are measured as changes in current.  Only 2 of 
the 4 recording sites are coated with glutamate oxidase, the other two are coated 
with the protein matrix alone to serve as sentinels for self-referencing.  In off-line 
data analysis, the current recorded on the sentinels is subtracted from that 
recorded on the coated sites.  The remaining current changes are attributed to 
glutamate release.  
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Surgery and in vivo recording 
 
 Upon demonstration of task proficiency, animals were acclimated to the 
test chamber. They were trained daily in the new environment until they re-
established criterion level performance (approximately 2 weeks). After no less 
than three consecutive days of criterion level performance in the test chamber, 
animals were implanted with a GO-coated microelectrode. Surgeries were 
performed under aseptic conditions. Isoflurane (1-5%) was used to induce 
anesthesia (Anesco/Surgivet, Waukesha, WI). Anesthetized rats with shaved 
heads were placed in a stereotaxic frame (David Kopf, Model # 962, Tujunga, 
CA). Their body temperature was maintained at 37ºC using Deltaphase 
isothermal pad (Braintree Scientific, Braintree, MA).  
Following cessation of the pedal reflex, the scalp was cleansed with 
betadine. A ~10 mm incision was made along the midline. Three stainless steel 
screws were threaded in the cranium. Additional holes were drilled above the 
right prelimbic cortex and above a remote spot in the left hemisphere to 
accommodate the Ag/AgCl reference electrode. The microelectrode assembly 
was slowly lowered into the prelimbic region of the right mPFC (AP: +3.0 mm; ML: 
-0.7 mm, measured from Bregma; DV: -3.5 mm, measured from dura) using a 
microdrive (MO-10; Narishige, International, East Meadow, NY) and anchored to 
the skull with dental cement. Topical antibiotic (bacitracin, polymixin and 
neomycin) was applied around the incision immediately after surgery. All animals 
given antibiotic (amikacin; 25 mg/kg; s.c.), an analgesic (buprenorphine, 0.01 
  83 
mg/kg; s.c.), and saline (1.0 mL; i.p.) for two days post-operatively while 
remaining in their home cages with food and water ad libitum. After a 48-hour 
recovery period, the water restriction schedule was resumed. On a test day, the 
animal was placed in the chamber and the microelectrode assembly connected 
to the FAST-16 system through a shielded cable, a low-impedance commutator, 
and a miniature headstage (mk-II RAT HAT; Quanteon, Lexington, KY). 
Recording sessions for the sustained attention task typically took place 3-5 days 
after surgery, allowing time for the animals to acclimate to the headstage. 
Amperometric recordings were collected every 500 ms (2 Hz sampling rate) 
applying a fixed potential of 0.7 V to the microelectrode using the FAST-16 
recording system. Data was captured using FAST-16 software. Amperometric 
recordings were time-locked by marking task events with TTL pulses. 
 
Analysis of Performance 
  
In each session, the total number of Hits, Misses, correct rejections (CR), 
false alarms (FA), and omissions were recorded. Using these values, the relative 
number of Hits [h/(h+m)], correct rejections [cr/(fa+cr)], Misses (1-h), and false 
alarms (1-cr) were determined.  An additional measure, the SAT score, was also 
calculated.  SAT scores take in to account performance on both signal and non-
signal trials and serve as an index of overall attentional performance.  Scores 
can range from -1 to 1, with 1 indicating all Hits and CR, 0 chance performance, 
and -1 all Misses and FA.   
  84 
 
Electrochemical signal processing 
 
 Current recordings from each platinum site were normalized by dividing 
the raw current value at each time point by the change in current following the 
addition of DA observed on that site during calibration. The normalized currents 
recorded from the non-GO coated sites were then subtracted from the 
normalized currents recorded at the GO-coated sites (“self-referencing”). These 
subtracted values were then converted to approximations of extracellular choline 
by dividing by the sensitivity of the GO-coated electrode determined in calibration. 
 
Trial by trial analysis of electrochemical data 
 
 Data was organized in 500 ms time bins, and normalized to the data point 
5 seconds prior to the signal or non-signal event (e.g. 7 s prior to lever extension 
on a non-signal trial) by setting this point equal to 0 and every point after the 
difference from this value. The glutamate concentrations for each data point over 
the 2 s prior to the onset of the signal (or the analogous time period on a non-
signal trial) were averaged together and served as the pre-trial baseline. 
Because we were interested in changes in glutamatergic activity proximal to cue 
and lever extension only the subsequent 4 s post-baseline were used for 
statistical analysis.  As noted in the description of the SAT above, there is a two 
second delay between cue and lever extension on a signal trial, thus this time 
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window includes an analogous 2 s time window following signal and lever 
extension.  Absolute changes in extracellular glutamate levels reported in the 
results are the difference between peak glutamate concentration value and the 
pre-cue baseline period.  A total of 154 Hits, 185 CR, and 95 Misses were 
included in the final analyses.  As in Chapter II, FA occurred only rarely (12.5% of 
electrochemical data available) and therefore were not included in the analyses.    
 
Statistical analysis 
 
 Performance during the SAT was analyzed with repeated-measures 
ANOVAs with block of performance (and stimulus duration for signal trials) as 
factors. The electrochemical data were analyzed with repeated measures 
ANOVAs with a factor of time (Baseline, followed by the 4 seconds post cue).   A 
significant change in extracellular glutamate levels relative to baseline would be 
indicated by a main effect of time.  
 Results of all statistical tests are reported with Huyhn-Feldt corrected 
values.  All post hoc analyses examining the change from baseline levels 
employed the least significant difference test (LSD). When warranted, main 
effects, interactions, and exploratory analyses were carried out with paired 
samples t-tests (α=0.05). 
 
Results 
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Performance 
 
The percentage of detected trials declined with shorter signal durations (M±SEM; 
500 ms Hits: 70.00±6.66%, 50 ms Hits: 55.00±6.72%, 25 ms Hits 52.56±7.95%). 
Animals correctly rejected 73.74±9.54% of non-signal events.  Animals also 
omitted very few trials (4.85±2.11% of trials/session).  Response latencies (time 
from extension of the response lever into the operant chamber to lever press) 
were fastest for hits (710.51±41.69 ms), most likely due to the fact that on 
detected trials, the animal can begin to initiate a response prior to lever extension.  
The latency to respond was similar across all other trial types always taking 
around 1 s (901.19 ± 24.98 ms).  
 
Glutamatergic activity during SAT performance 
 
Hits 
   
 As illustrated in figure 3.3a, the concentration of extracellular glutamate 
increased following the signal on a Hit (main effect of time (F(9,1377)=12.00, 
p<0.001)).  Glutamate was significantly increased by 500 ms following cue offset, 
peaked after lever extension (2.5 s post cue, 72.53 ± 16.31 nM above baseline), 
and declined following response and reward.   Additionally, determination of the 
onset and peak of glutamatergic transients (aim 2) is based upon the averaged 
population trace and not data from individual trials.    
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Influence of trial sequence  
  
 A trial by trial analysis indicated a significant amount of variability in the 
amplitude of cue evoked glutamate release on Hits.  Given the trial sequence 
dependency of cholinergic transients, we next examined glutamate release on 
hits based upon the preceding trial type. In contrast to cholinergic transients, 
glutamate release events on hit trials are not modulated by trial sequence.  On 
Hits that were preceded by a CR (Figure 3.3b), glutamate levels began to rise 
following the offset of the cue, peaking after the extension of the response levers 
(time point 2.5 s post cue, 85.38±23.31 nM above baseline), and then rapidly 
declined (main effect of time; F(9,540)=5.442, p<0.001, time point 0.5 s - 2.5 s 
LSDs all p’s <0.05). There were relatively few Hit trials preceded by Misses that 
were available for analysis (total of 18).  As a result, statistical tests did not 
indicate a robust increase in extracellular glutamate levels on such hits, although 
as is evident in Figure 3.3c, there was a similar pattern in glutamatergic activity 
following the cue on a detected trial (peak at time point 1.5 sec post cue, 
85.50±60.36 nM above baseline). Finally, on Hits preceded by another Hit (3.6d), 
glutamate began to rise after the cue, peaking around the time of the extension 
of the response lever (main effect of time; F(9,423)=5.480, p<0.001. Time points 
0.5-3 s, all p’s <0.03).    
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Figure 3.3 
On signal trials resulting in a hit, extracellular glutamate levels began rising with 
the onset of the cue, peaking at the time of lever extension and response (A). 
Unlike cholinergic transients on hits which are only seen on hits preceded by CR 
or Misses, all hit sequences are associated with transient increases in glutamate 
release (B-D).   
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Influence of signal duration on the amplitude of evoked glutamate release 
on Hits 
 
 In the SAT, the duration that the cue light is illuminated is varied (either 
500, 50, or 25 ms) In terms of performance, the proportion of Hits varied by 
signal duration, with more Hits on trials with the longest signals. As shown in 
Figure 3.4, the amplitude of the glutamate release event also varied as a function 
of signal duration. Following a 500 ms signal (Figure 3.4b), glutamate began to 
rise immediately and peaked 2.5 s later, 100.65±26.78 nM above baseline (Main 
effect of time: F(9,522)=6.768, p<0.001,  LSDs: time point 0.5 sec p=0.025, time 
points 1.5 -3 s, all p’s <0.044).  For 50 ms Hits (Figure 3.4c), the evoked 
glutamate response was on average smaller,  peaking 2 s post cue, 89.20 ± 
30.35 nM above baseline (Main effect of time; F(9,414)=3.567, p=0.001.  Time 
points 2 s and 2.5 s post cue, both p’s <0.011). The magnitude of the increase 
was even smaller on 25 ms Hits (3.4d). Although levels of glutamate trend 
towards an increase following the cue no individual point actually reached 
statistically significant levels above baseline.  The closest time point was the 
peak at 2 s post cue (p=0.105), 42.86±47.81 nM above baseline concentrations. 
As a reminder, as of now we only have data from 3 animals in 3 recording 
sessions.  It is our belief that the trend in the amplitude of the release event is 
strong enough that the differences between Hits following different signal 
durations will be become more obvious with the addition of more data.  
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Figure 3.4 
 
Detected cues evoked transient increases in glutamate release (A).  Additional 
analyses suggest that the amplitude of cue-evoked glutamate release varies as a 
function of signal duration, with the amplitudes following 500 ms signals (B) being 
larger than those following  50 ms signals (C).  For 25 ms signals (D), 
concentrations of extracellular glutamate did not exceed those at baseline.   At 
this point, it is speculated that this is due to the relatively few number of trials 
included in the overall analysis, and addition of more data will show that these 
brief signals evoke small, but robust, increases in glutamate. 
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Glutamatergic activity on Correct Rejections and Misses  
  
 We were surprised to find in contrast to our preliminary hypothesis, and to 
the pattern of cholinergic activity, there was also a change in glutamate 
concentration on CR trials (Figure 3.5a).  This elevation was coincident with 
extension of the response lever into the operant chamber (main effect of time 
(F(9,1656)=39.86, p<0.001; time of lever extension2 s post, all LSDs p<0.001).  
This increase peaked at 1 s after lever extension, 302.48±34.17 nM above 
baseline.   
 The results from Misses were also unexpected (Figure 3.5b).  We had 
predicted that on a Miss, the cue would evoke a small amount of glutamate 
release, however much less than on a hit, and presumably not enough to engage 
transient cholinergic mechanisms.  However, glutamate release on Miss trials 
was remarkably similar to that observed on CR at the time of lever extension 
(main effect of time (F(9,846)=9.57, p<0.001; time of lever extension2 s post, 
all LSDs p<0.001)..  There was no change following cue presentation. This 
increase peaked at 1.5 s after the lever had been extended into the chamber, at 
291.11 ± 83.61 nM above baseline.  
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Figure 3.5 
Contrary to our hypothesis, both CR (A) and Misses (B) were associated with 
glutamatergic transients during the period the levers were extended in to the 
chambers.  Interestingly, for both CR and Misses, this time point coincides with 
the first indication to make a response.    
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Cue-evoked glutamate release during periods of good vs. poor 
performance 
 
 According to our model (Figure 3.1), the amplitude of glutamatergic 
transients should be modulated by tonic cholinergic activity.  To address this 
issue, we conducted a preliminary analysis comparing glutamatergic transients 
recorded during periods of “good” vs “poor” performance. “Good” versus “poor” 
performance was defined using the SAT score.  Again, this measure collapses 
performance on both signal and non-signal trials into a score ranging from -1 to 1, 
with 1 indicating perfect response accuracy, 0 random lever selection, and -1 
perfectly wrong performance.  The behavioral data from each animal was broken 
down in to 3 min blocks. SAT scores lower than 0.35 were defined as periods of 
poor performance. Animals typically exhibited 2-3 such periods per session. 
Overall, periods of good performance were characterized by SAT scores of 
0.57±0.02, while periods of poor performance had a mean SAT score of 
0.19±0.03 (Figure 3.6a F(1,2)=476.67, p=0.002).  
 Electrochemical data was then separated based on trial type from periods 
of good or poor performance. We next wanted to directly compare the amplitude 
of cue evoked glutamate on Hits from each. However, during periods of poor 
performance, animals had fewer Hits overall, most notably on 500 ms and 25 ms 
signal duration trials. Because the amplitude of glutamate on Hits appears to vary 
by signal duration, equivalent numbers were randomly selected and used for 
statistical comparison.  The peak amplitude of glutamate release on Hits during 
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periods of good performance (Figure 3.6b) was 98.08 ± 23.87 nM above baseline, 
compared to 54.57±21.99 nM during periods of poor performance (Figure 3.6c; 
performance X interaction; F(9,639)=2.068, p=0.039).  
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Figure 3.6 
Performance varied across the behavioral test session.  Good performance and 
poor performance periods were defined based upon SAT scores.  SAT scores 
range from -1 or 1, with 1 representing all Hits and CRs, 0 chance performance, 
and -1 all Misses and FA.  Good periods of performance were characterized by a 
SAT score of 0.57±0.021, while the SAT score during periods of poor 
performance hovered around chance (0.19±0.03) (A).  During periods of poor 
performance, the amplitude of evoked glutamate release on hits was attenuated 
(C) in comparison to periods of good performance (B).  
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Discussion 
 
Summary 
  
 Here we report that cues evoke glutamatergic transients in all detected 
signal trials, irrespective of sequence. The amplitudes of glutamatergic transients 
in trials that ended with a Hit were larger for cues with longer durations (e.g. 
500>50>25 ms). On signal trials resulting in a Miss, or non-signal trials resulting 
in a CR, lever extension, representing the first indication that the animal can 
respond, also evoked a robust increase in glutamate release.  Furthermore, we 
compared the amplitudes of glutamatergic transients from trials yielding hits 
during periods of high levels of performance (Figure 3.6b; SAT scores >0.35 
averaged over all durations) with periods of near random performance (SAT 
scores: <0.35). The amplitudes of glutamatergic transients were markedly lower 
during poor performance periods (Fig. 3.6c).  The discussion to follow will 
compare the characteristics of cholinergic and glutamatergic activity and address 
their potential relationship to one another.  It will begin with the patterns that were 
predicted by our initial hypotheses, and follow with observations that deserve 
further explanation 
  
Direct comparison of Cholinergic and Glutamatergic activity 
Time course and tonic modulation 
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 Based upon previous studies in anesthetized animals we hypothesized 
that cue evoked glutamate release stimulates a cholinergic transient (recall figure 
3.1, cue evoked glutamate release (blue projection) drives cholinergic signaling 
through stimulation of ionotropic glutamate receptors situated on cholinergic 
inputs (red projection)).  Examination of the timing of the onset of the two release 
events (glutamateACh) supports this hypothesis.  Cue evoked glutamate 
release on Hit begins immediately following the offset of the detected stimulus, 
reaching levels significantly above baseline by 500 ms post-cue.  Cholinergic 
transients begin to rise approximately 1 s after cue offset and reach levels above 
baseline by ~2 s.  Thus in terms of time course, it seems possible that detected 
cue-evoked glutamate release in turn recruits local cholinergic mechanisms to 
produce a cholinergic transient. 
 We predicted that amplitudes of cue-evoked glutamate release on Hits 
would be larger during periods of good performance compared to periods of poor 
performance due to tonic cholinergic modulation of glutamate release (Figure 3.1, 
purple projection).  During periods of good performance, the amplitude of cue 
evoked glutamate release was almost twice as large as during periods of poor 
performance (change from baseline; good performance:   98.08 ± 23.87 nM, poor 
performance: 54.57 ± 21.99 nM).  Based upon these data, it does seem plausible 
that tonic cholinergic activity modulates cue-evoked glutamate release during 
SAT performance.  
                 
Effect of signal duration 
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 We had predicted that the amplitude of glutamate release would be signal 
duration dependent, given the signal duration dependent Hit rates that 
characterize task performance.  Indeed, the amplitude of cue-evoked glutamate 
on Hits is largest following 500 ms signals, and smallest for 25 ms signals.  
Cholinergic transients (based upon the current data) are not modulated by signal 
duration.  This pattern suggests that the amplitude of glutamate release dictates 
the probability of generating a cholinergic transient. 
 
Glutamate release events are not sequence dependent  
 Cholinergic transients are observed only on Hit trials that are preceded by 
CR and Misses. Glutamatergic transients are observed on all hits, regardless of 
sequence.  This introduces a complication and suggests additional modulation at 
prefrontal synapses acting to selectively suppress cholinergic activity on HitHit 
sequences.  Possible mechanisms accounting for this are explored in the 
General Discussion. 
 
A separate role for glutamate? 
  
 One of the most striking differences between the patterns of glutamate 
and ACh release events in the SAT is the presence of a large glutamatergic 
transient at lever extension on CR and Misses, where we see no measurable 
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change in cholinergic activity.  This suggests that in addition to any potential 
mediation of cholinergic release events, glutamatergic signaling must also play a 
separate role in supporting task performance.   To examine the glutamate data 
on its own: On Hits, a glutamatergic transient is generated by the detected cue.  
This transient peaks at the time of lever extension, and then sharply drops off 
following lever press and reward.  On a CR, a large transient is evoked by the 
lever which peaks during the response period and then begins to decline 
following lever press and reward.  On a Miss, again a large transient is evoked by 
the lever.  .   
 The cue-light on a Hit and the lever on a CR represent the first signal to 
initiate a choice or a decision and are coincident with the initiation of a response 
(note; the lever does not evoke a glutamate release event on Hits).  This signal is 
maintained until the choice is made and declines after receiving feedback that 
the choice was correct.  On a Miss, the lever provides the same information that 
it is time to make a choice.  However, after the response is made, the reward is 
not presented, and suggests that glutamate release does not necessarily need to 
be concurrent with reward.         
 
Concluding Remarks 
 
 We began with a fairly straightforward hypothesis based upon earlier work.  
Results from anesthetized studies determined that mediodorsal thalamic input is 
required for the generation of cholinergic transients (Parikh, et al., 2010). This 
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glutamatergic input was hypothesized to recruit local prefrontal cholinergic 
mechanisms, subsequently generating a cholinergic transient. Mediodorsal 
thalamic inputs express α4β2 nicotinic receptors, thus tonic cholinergic activity 
can positively modulate the glutamatergic representation of the cue and vary the 
probability of signal detection (or an attention mode shift).  Some of our 
hypotheses were supported. Glutamate release precedes cholinergic release and 
thus it is feasible that cue-evoked glutamatergic transients stimulate cholinergic 
transients under some conditions (i.e. Hit trial following a CR or a Miss).  The 
amplitude of glutamate release is also tightly correlated with signal duration 
dependent hit rates; larger glutamate release events are more likely to generate 
a cholinergic transient and a Hit on 500 ms trials, while the smaller release event 
on 25 ms makes a cholinergic transient and a Hit less likely.  This speculation is 
of course restricted to trials  requiring a shift from cue-independent to cue-
dependent processing given the trial sequence dependency of cholinergic 
transients.   
 Based upon the results from anesthetized studies showing the 
mediodorsal thalamic input is necessary for the generation of cholinergic 
transients (Parikh, et al., 2010), such glutamate release is hypothesized to be 
necessary for generating cholinergic transients in SAT performing animals. The 
presence of large glutamate release events at lever extension on CR and Misses 
indicates that it is not sufficient, and further suggests a separate or additional role 
for glutamate in task performance other than cholinergic activation.  Future 
experiments, including how thalamic lesions impair task performance as well as 
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glutamatergic and cholinergic transients in task performing animals, will be 
necessary to resolve the complex relationship between cholinergic and 
glutamatergic signaling.   
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Chapter IV: Enhancement of attentional performance by selective 
stimulation of α4β2 nAChRs: underlying cholinergic mechansims  
 
Summary 
 
 Impairments in attention are a major component of the cognitive 
symptoms of neuropsychiatric and neurodegenerative disorders. The non-
selective nicotinic acetylcholine receptor (nAChR) agonist nicotine has frequently 
been demonstrated to facilitate aspects of attention in humans and animals; 
however, these effects often were difficult to demonstrate and remained relatively 
small. Using an operant sustained attention task (SAT), including a distractor 
condition (dSAT), that was previously cross-validated for research in animals and 
humans, administration of the selective α4β2* nAChR agonist S 38232, but not 
nicotine, was found to robustly benefit the attentional performance of intact rats, 
specifically during the recovery of performance following distractor presentation. 
Consistent with evidence indicating the role of transient increases in cholinergic 
activity in attentional performance, and the cholinergic mediation of effects of 
nAChR agonists, S 38232 enhanced the detection of signals specifically in trials 
that involved shifts from cue-independent to cue-dependent attention. 
Electrochemical recordings of prefrontal cholinergic activity evoked by S 38232 
and nicotine indicated that the α4β2* nAChR agonist evoked profoundly 
"sharper" increases in release, mirroring those that mediate shifts in attention. By 
co-administering the α7 nAChR antagonist MLA, the release events evoked by 
  105 
nicotine are “sharpened”. Accordingly, co-administration of nicotine and MLA also 
enhanced the recovery of attentional performance following distracter 
presentation.  These results indicate that compared with nicotine, α4β2* nAChR 
agonists produce significant enhancement of attentional performance and that 
the dSAT represents a useful behavioral screening tool. Finally, the 
electrochemical evidence supports the hypothesis that nAChR agonist-evoked 
increases in cholinergic activity that closely mimic those seen in performing 
animals predict greater pro-attentional efficacy than agonists evoking longer 
lasting increases in cholinergic neurotransmission. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  106 
 
INTRODUCTION 
 
 Efforts to discover and develop treatments for the cognitive symptoms of 
neuropsychiatric and neurodegenerative disorders have been hampered by the 
absence of effective "benchmark" drugs and the unavailability of preclinical 
screening and characterization procedures that reliably predict clinical efficacy of 
putative cognition enhancers. Furthermore, comprehensive theories that would 
define promising target mechanisms for the development of cognition enhancers 
have remained rare (Hagan & Jones, 2005; Sarter, 2006).   
 Attentional functions and capacities are key variables of cognitive 
performance (Sarter, 2006; Sarter, et al., 2005), and as such have been 
extensively targeted for drug induced cognition enhancement.  Cholinergic 
activity is necessary for the performance of attention tasks (McGaughy, et al., 
1996; Sarter, 2006; Sarter, et al., 2005).  The development of enzyme-coated 
microelectrodes for monitoring real-time acetylcholine (ACh) release revealed 
that brief (on the scale of seconds) increases in cholinergic activity (henceforth 
called ‘transients’) mediate the detection of cues in attentional contexts (Parikh, 
et al., 2007).  This finding helped explain the exclusive impairment in the ability to 
report the presence of a signal observed after cholinergic lesions, whereas non-
signal trial-response accuracy remains completely spared (McGaughy, et al., 
1996).  More recent evidence recording transients from animals performing the 
SAT has further refined this theory (see below).  
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 The demonstration of the beneficial attentional effects of nicotine, the most 
extensively studied nicotinic acetylcholine receptor (nAChR) agonist, in healthy 
humans, patient groups, as well as in intact animals and animal models, has 
been less than straight forward. The magnitude of the effects of nicotine often 
remained relatively small and depended on individual task parameters, treatment 
regimen and the subjects’ prior exposure to nicotine (Mirza & Stolerman, 1998; 
Sarter, Parikh, et al., 2009). In contrast, accumulating evidence indicates that 
selective agonists at α4β2* nAChRs more robustly and reliably enhance 
attentional performance in patients and laboratory animals (Grottick & Higgins, 
2000; Lippiello, Letchworth, Gatto, Traina, & Bencherif, 2006; McGaughy, et al., 
1999; Potter, et al., 1999; Prendergast, et al., 1998; Wilens, et al., 1999; Wilens 
& Decker, 2007; Wilens, Verlinden, Adler, Wozniak, & West, 2006).  
 Local administration of α4β2 nAChR agonists evoke abrupt increases in 
cholinergic activity within the cortex that mirror, specifically in terms of rise time, 
amplitude, and decay rate, the ‘sharp’ transients observed in task performance 
(Parikh, et al., 2008).  In contrast, nicotine generates long-lasting release events 
(up to and over 1 min) that are partly mediated through stimulation of the α7 
nAChR (Parikh, et al., 2010; Parikh, et al., 2008).  On the basis of these and 
additional results we hypothesized that α4β2 agonists more robustly enhance 
attentional performance than nicotine, as the long release events supported by 
nicotine may limit its ability to enhance trial-based performance in tasking 
involving cholinergically mediated cognitive operations occurring on much shorter 
time scales (Sarter, Parikh, et al., 2009).  
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 The first aim of the present study was to compare the effects of a full 
agonist at α4β2 nAChRs, S 38232, with the effects of the non-selective agonist 
nicotine on the performance of rats in the distractor version of the sustained 
attention task (dSAT). This task was originally developed for research in animals, 
has been cross-validated for research in humans (Demeter, et al., 2008), and 
recently was suggested by the CNTRICS Initiative (Cognitive Neuroscience 
Treatment Research to Improve Cognition in Schizophrenia) for research 
concerning 'control of attention' (for details see (Nuechterlein, et al., 2009). The 
stabilization and recovery of attentional performance following distractor 
presentation is thought to be mediated, top-down, via activation of prefrontal 
networks (Demeter, et al., 2011; Johnston, Levin, Koval, & Everling, 2007; 
Weissman, Warner, & Woldorff, 2004).  As high demands on cognitive 
performance are a major determinant of showing attentional benefits of nicotine 
in healthy subjects (Newhouse, Potter, & Singh, 2004), dSAT performance was 
expected to reveal such effects. The second aim of this study was to determine 
the properties of cholinergic release events evoked by the nicotine and S 38232. 
Third, we tested the hypothesis that co-administration of nicotine and the α7 
nAChR antagonist MLA results in greater pro-attentional effects due to the 
honing nicotine-evoked ACh release by α7 nAChR blockade.   
 Finally, in animals performing the SAT, transient increases in prefrontal 
cholinergic activity were observed specifically in signal trials that yielded a hit (or 
a detection) if such trials were preceded by non-signal trials yielding correct 
rejections, or by signal trials yielding misses (see Chapter 2). This finding 
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suggests that prefrontal cholinergic transients shift prefrontal circuitry into a mode 
that allows cues to control attention (cue-dependent attention), and away from a 
mode that controls attention based on task rules not involving cue detection (cue-
independent attention).  Therefore, a final analysis explored the possibility that 
that the beneficial effect of the α4β2 nAChR agonist is due to the facilitation of 
performance on trials requiring such shifts.   
 
METHODS 
Subjects 
 
 For the behavioral experiments, subjects were male Wistar rats (Harlan, 
IN) approximately 200-300 g at the onset of training. Animals were kept on a 
14:10 light/dark cycle in a temperature and humidity-controlled vivarium. Water 
was available only as a reward during testing and for 30 min upon the completion 
of a training/testing session. Food was available ad libitum. All training and 
testing took place during the light cycle. Subjects used for electrochemical 
studies were adult male Fisher/Brown Norway hybrid rats (FBNF1; Harlan, IN; 
n=21) approximately 200-250 g at the beginning of the experiments. Food and 
water was available ad libitum. All animals were maintained in accordance with 
the NIH guide for the Care and Use of Animals and experiments were conducted 
in accordance with protocols approved by the University of Michigan Committee 
on Use and Care of Animals (UCUCA). 
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Sustained attention task (SAT) acquisition and performance criteria 
  
 Animals were trained in the same operant chamber daily.  In the first stage 
of training animals were shaped to press each of the two response levers to gain 
access to a water reward.  A press on either lever led to access to 0.1 mL of 
water (FR-1 schedule), with the rule that if at any time there were 5 more presses 
on one lever relative to the other,  the lever becomes inactive until the other is 
pressed. This rule was designed to discourage the development of a lever or side 
bias. This phase of training continued until animals reached the criterion of 120 
rewards per session (approximately 45 min) for two consecutive days.  
In the second stage of training, animals had to discriminate between 
signal (illumination of central panel light) and non-signal (no illumination of 
central panel light) trials. Each session included 160 trials equally divided 
between signal and non-signal. Correct responses were rewarded with water. On 
a signal trial, the signal light was turned for 1 second, followed two seconds later 
by the extension of the response levers into the chamber. A press on the left 
lever was considered correct, and scored as a Hit. A press on the right lever was 
scored as a Miss. On non-signal trials, a press on the right lever was considered 
correct, and the trial scored as a correct rejection (CR). A press of the left lever 
was considered incorrect, and scored as a false alarm (FA) (note: half of all 
animals were trained with non-signal and signal response levers in the reverse 
position). The levers were retracted after being depressed regardless of whether 
the response was correct or incorrect. If no press occurred after four seconds, 
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both levers were retracted and the trial was scored as an omission. Incorrect 
responses were followed by correction trials identical to the previous trial. After 
three consecutive errors on correction trials, animals were given a forced choice 
trial. The inter trial interval (lTI) was 12±3 s during this stage of training. 
Performance criterion for this stage was >70% hits and correct rejections for 
three consecutive sessions.  
In the third stage of training the ITI was decreased to 9±3 s and there 
were no correction or forced trials. The signal duration remained 1 s and 
sessions consisted of a total of 162 trials. As with the previous stage, criterion for 
advancement was >70% hits and correct rejections for three consecutive 
sessions. 
In the final version of the task, signal duration was shortened and varied 
(500, 50, or 25 ms). Training sessions were timed to 40 minutes, equivalent to 
~200 trials, half signal and half non-signal. Animals were trained on the final 
version of the task until performance reached a plateau. Only animals with >70% 
hits to 500 ms signals and >70% correct rejections were employed in the present 
experiments. After reaching criterion animals continued daily practice sessions 
and were habituated for one week to systemic injections (i.p.) of saline. 
 
Assessment of performance during the distractor condition (dSAT) 
 
 In the dSAT, the first 8-min block of trials (block 1) was identical to the 
SAT described above. This block was followed by a 16-min block (block 2) with 
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the distractor (chamber houselight flashing on/off at 0.5 Hz) turned on. Following 
distractor termination, performance recovery was determined during a final 16-
min block of the regular SAT (block 3). Animals practiced the dSAT a minimum of 
two times before the effects of S 38232 and nicotine on performance were tested. 
Individual distractor test sessions were separated by a minimum of 2 days/SAT 
practice sessions, with performance at or above criterion level. Importantly, our 
evidence suggests that repeated exposure to the distractor does not significantly 
alter the efficacy of the distractor or the rate of post-distractor performance 
recovery. 
 
Measures of SAT and dSAT performance 
 
 Data from both SAT and dSAT test sessions were grouped into three 
blocks of trials for analysis; the first 8 minutes of task performance (block 1), the 
second 16 minutes of task performance (block 2), and the final 16 minutes of 
task performance (block 3). For each session, the total number Hits and Misses 
by signal duration, CR, FA, and omissions, were recorded. Using these values, 
the relative number of Hits (h=H/(H+M)), correct rejections (CR=CR/(FA+CR)), 
misses (1-Hits), and false alarms (1-CR) were determined. To generate an index 
of the animals’ overall performance on both signal and non-signal trials, a 
sustained attention task score (SAT, dSAT for distracter sessions) was 
calculated (SAT or dSAT= (Hits-FA)/(2(Hits+FA)-(Hits+FA)2)). SAT/dSAT scores 
range from -1 to 1, with 1 indicating perfect accuracy in signal and non-signal 
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trials, 0 chance performance, and -1 depicting that all responses were incorrect 
(misses and false alarms). The SAT/dSAT score is a variation of the sensitivity 
index (Frey, 1973) and is based upon the relative number of hits and false alarms, 
as opposed to the probability of such responses, and thus is not confounded by 
errors of omission. Scores were calculated for each block of trials, signal duration, 
as well as averaged across signal durations. 
 
Analysis of the probability of a hit depending on prior trial outcome 
 
 We hypothesized that nAChR agonist-induced enhancement in 
performance manifests primarily in terms of increases in hits (event 1), and 
specifically if such hits were preceded by non-signal trials resulting in a correct 
rejection (event 2). Employing the multiplicative law of probability (see Chapter 2 
for further explanation), the joint probability for two such events, as well as for 
several control events, was calculated (Howell, 1989). 
 
Drugs, drug administration, and doses 
  
 S 38232, a pyridinylamino-cyclopropanamine derivative, was obtained 
from Institut deRecherches Internationales Servier (Courbevoie, France). The 
compound is a full agonist at α4β2 nAChRs (Lagostena, et al., 2010) with an 
EC50 of 3.4x10-6 M to rat α4β2 nAChRs expressed in Xenopus Laevis oocytes. 
Furthermore, the compound has a low partial agonist activity at rat α7 nAChR 
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(EC50 of 1.3x10-4 M). Nicotine (nicotine hydrogene tartrate; Sigma-Aldrich, St. 
Louis, MO) and S 38232 were administered to two groups of animals. SAT 
performance was determined after administration of S 38232 (n=11; 0.03, 0.30, 
1.00, and 3.00 mg/kg) or nicotine (n=14; 0.02, 0.10, 0.40 mg/kg; base weights). 
Both compounds were dissolved in sterile saline. Animals were given a systemic 
injection (i.p.) and placed into the operant chambers for the duration of a pre-task 
wait period (15 min for nicotine, 30 min for S 38232). The administration of doses 
and vehicle was randomized for each animal. Successive administrations of drug 
doses were separated by a minimum of 2 days/sessions where the animal’s SAT 
performance was at or above criterion level. Vehicle was administered prior to all 
other test sessions. The selection of doses for dSAT testing was based on 
effects on SAT performance and therefore is explained in Results.  Finally, we 
tested the effects of nicotine (0.1 mg/kg) administered together with the α7 
nAChR antagonist MLA citrate hydrate (MLA; Sigma-Aldrich; n=9; 1.0 or 5.0 
mg/kg; 1ml/kg for all injections; 15 min before task onset).  All compounds were 
dissolved in sterile saline. The pH of the solutions (7.4-7.6) was adjeusted using 
sodium hydroxide solution.  These effects were determined in animals that also 
received nicotine alone before a dSAT performance test to allow for within-
subjects comparisons.  
 
Electrochemical recordings of nAChR agonist evoked cholinergic 
transients in vivo 
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 Cholinergic transients were measured using ceramic based choline 
selective microelectrodes and fixed-potential amperometry (Quanteon, 
Nicholasville, KY). Each electrode was equipped with four platinum recording 
sites arranged in side by side pairs. Choline oxidase (CO) was cross-linked with 
a bovine serum albumin (BSA)/glutaradehyde solution and immobilzed on the 
bottom pair of recording sites. The other pair was coated with the 
BSA/glutaraldehyde solution alone and served to record fluctuations in 
background current. Meta-phenylene diamine (mPD) was electropolymerized 
onto the surface of the recording sites to block electroactive interferents. 
Electrodes were calibrated in vitro and characterized by a sensitivity for detecting 
choline of 8.57±1.40 pA/µM, a selectivity of choline:AA of 512.32±276.93, and a 
highly linear response to increasing choline concentrations (20-80 µM): R2: 
0.957±0.012.  Animals were anaesthetized with urethane (1.25-1.5 g/kg; i.p.) and 
placed in a stereotaxic frame. Body temperature was maintained at 37 °C with an 
isothermal pad. Single barrel glass capillaries (1.0 mm X 0.58 mm, 6 in; A-M 
systems, Inc., Carlsborg, WA) were pulled using a micropipette puller (Model # 
51210, Stoelting, Wood Dale, IL). Micropipettes (inner tip diameter ~15 ìm) were 
attached to the microelectrode with the tip centered between the two pairs of 
recording sites, ~70 ìm from the surface of the electrode. The assembly was 
positioned in either the right or left medial prefrontal cortex (AP: +3.0 mm, ML ± 
0.7 mm, DV: -3.0 mm from bregma). An Ag/AgCl reference wire was implanted in 
the opposite hemisphere, and a fixed potential of +0.7 V was held between the 
reference and recording electrodes. Amperometric recordings were made at 1Hz, 
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and data was digitized using a FAST-16 recording system (Quanteon LLC, 
Nicholasville, KY). Experiments began following stabilization of baseline current 
(45-60 min). Drug solutions were pressure-ejected through the micropipettes and 
ejection volumes were monitored via a stereoscope equipped with a reticule.  S 
38232 was delivered via intracranial pressure ejections of 200 nL of drug solution 
(40 pmol, n=5; 200 pmol, n=6, and 2 nmol, n=5). Cholinergic transients evoked 
by S 38232 were compared to those evoked by identical amounts of nicotine 
(data taken from Parikh et al, 2008). In addition, the effects of dihydro-â-
erythoidine (DHβE), a relatively selective β2 nAChR antagonist, on signals 
evoked by S 38232 was assessed. DHβE (Tocris Bioscience; Ellisville, MO) was 
infused (1.6 nmol in 800 nL over 5 s), and was followed 3 min later by a series of 
3 pressure ejections of S 38232 (2 nmol, n=5). Current recordings on CO-coated 
channels were self-referenced by subtracting the current recordings from the 
sites coated with the protein matrix alone. Transients evoked by S 38232 or 
nicotine were compared with respect of peak amplitudes and signal decay rate 
(t50; time required for the signal to decline by 50% of peak amplitude). Data from 
3 cholinergic signals per drug manipulation and per animal were averaged and 
used for statistical analysis. 
 
Statistical methods 
 
 Performance was analyzed using repeated measures ANOVAs with dose 
of drug, performance block, and signal duration as within-subjects factors. Mixed 
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model ANOVAs with the between-subjects factor of group were used to 
demonstrate that baseline performance did not differ between animals treated 
with nicotine or S 38232. One-way ANOVAs with dose as a between subjects 
variable were used to determine dose-response relationships and to compare 
evoked cholinergic transients evoked by the two nAChR agonists. All post hoc 
analyses employed the least significant differenced test (LSD). When necessary, 
main effects and interactions were further investigated with independent and 
paired samples t-tests (α=0.05). Exact p-values were reported. 
 
RESULTS 
 
Baseline SAT performance 
 
 Following the administration of vehicle, SAT performance did not differ 
between animals being treated with nicotine and S 38232, with respect to the 
overall SAT score or the individual measures of accuracy in signal (hits) and non-
signal trials (correct rejections; all effects of group p>0.13). Likewise, the effects 
of group did not interact with any of the task parameters (signal duration or block; 
all p>0.21). SAT and Hit scores declined significantly with decreasing signal 
duration (SAT: F(2,46)=112.67; p<0.001; hits: F(2,46)=184.09; p<0.001; see 
Figure 4.1a). Animals correctly rejected 88.37±1.21% of non-signal events 
(Figure 4.1b). SAT performance did not vary across the 3 blocks of trials, and the 
effects of block did not interact with group and/or signal duration (all p>0.45). 
Finally, animals omitted few trials (0.88±0.26% of ~200 trials/session) and the 
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number of omissions did not differ between the groups (p=0.44). 
 
Effects of nicotine on SAT performance 
 
 Administration of the non-selective nAChR agonist nicotine (0.02, 0.1, 0.4 
mg/kg) did not enhance SAT performance (dose: F(3,39)=1.31; p=0.28). Further, 
as illustrated in Figure 4.1c, the highest dose of nicotine produced a small, but 
robust decrease in the Hit rate to longest signals (dose X signal: F(6,78)=5.50; 
p<0.001; post hoc comparisons indicated on figure).  Furthermore, all three 
doses of nicotine resulted in a decrease in the relative number of CR during 
block 1.  These effects were not seen during subsequent blocks of trials (dose: 
F(3,39)=5.63; p=0.013; dose X block: F(6,78)=6.42; p<0.001; Figure 4e).  Finally, 
the highest dose of nicotine also increased the number of omitted trials 
(F(3,39)=8.05; p=0.014), from 0.66±0.29% after vehicle to 12.29±4.07% after 
administration of 0.4 mg/kg). 
  
Effects of S 38232 on SAT performance 
 
 Administration of S 38232 (0.03, 0.3, 1.0 and 3.0 mg/kg) did not affect Hits 
(Figure 4.1d; all main effects and interactions including dose: p>0.10).  However, 
the highest dose of S 38232 resulted in  a small yet significant decrease in the 
relative number of CR during the second block of trials (Figure 4.1f; dose: 
F(4,40)=0.84; p=0.49; dose X block: (F8,80)=2.31; p=0.03). The number of 
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omitted trials increased over blocks of trials (F(2,20)=5.30; p=0.02), from 
1.46±0.66% in block 1 to 2.26±0.65% in block 3; however, this increase was not 
affected by the administration of S 38232 (F(8,80)=1.90; p=0.15). 
 Taken together, neither the administration of the selective α4β2* nAChR 
agonist nor the non-selective agonist nicotine benefited SAT performance. 
Following the administration of the highest dose of either compound, relatively 
small-sized impairments in SAT performance were observed and remained 
limited to a particular block of trials. 
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Figure 4.1 
Baseline SAT performance and effects of S 38232 and nicotine.  (A) Depicts 
baseline Hit rate as a function of signal duration.  (B) CR rate over the three 
blocks of trials.  Baseline performance did not differ between the groups treated 
with S 38232 and nicotine.  (C) Administration of the high dose of nicotine 
decreased the number of Hits on 500 ms signals.  (D) Administration of S 38232 
did not affect Hits. (E) All doses of nicotine decreased the CR in the first block. (F) 
There was a small decrease in the number of CR in block 2 after the highest 
dose of S 38232.  (*p<0.05, **p<0.01, ***p<0.001).  
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Distractor-induced impairment and performance recovery 
 
 The dSAT baseline (vehicle) performance did not differ between animals 
scheduled to be treated with S 38232 or nicotine (all main effects of group and 
interactions involving group: p>0.20). As illustrated in Figure 4.2a and b, 
presentation of the distractor resulted in robust decreases in both the relative 
number of Hits and CR.  Concerning Hits, the effect of block interacted 
significantly with signal duration (block: (F(2.46)=23.66; p<0.001; block X signal: 
F(4,92)=16.21; p<0.001). Post hoc comparisons (illustrated in 4.2a) indicated an 
acute decrease in Hits during the distractor block and a partial but incomplete 
recovery of the Hit rate to longest signals during the post-distractor block.  In 
contrast, Hits to medium signals did not recover and Hits to the shortest signals 
were lower during the post-distractor block than during both preceding blocks of 
trials.  In contrast, the distractor-induced decrease in CR recovered completely 
during block 3 (main effect of block: (F(2.46)=73.26; p<0.001); Figure 4.2b).   
 
Facilitation of dSAT performance by S 38232 
 
 Based on the detrimental effect of the highest dose of S 38233 on SAT 
performance (see above), and inspection of (insignificant) effects of dose on all 
measures of SAT performance, a dose of 0.3 mg/kg was selected for dSAT 
testing. In the analysis of effects on dSAT performance, putative drug effects 
were expected to interact with the factor 'block', reflecting that drug effects would 
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manifest in the presence of, or subsequent to, distractor presentation. Such an 
interaction was found with respect to Hits (F(2,20)=6.68; p=0.006).  
 As would be expected, based on the effects of this dose of S 38232 on 
SAT performance (above),  post hoc comparisons did not indicate an effect of S 
38232 on Hits in the pre-distractor period (block 1).  Likewise, S 38232 did not 
affect the low number of Hits during the presence of the distractor in block 2.  
However, S 38232 enhanced the Hit rate during the post-distractor block 3 
(F(1,10)=7.09; p=0.024; Figure 4.2d).  
 
Effects of nicotine on dSAT performance 
 
 As illustrated in Figure 4.1c, SAT performance was robustly impaired by 
administration of the highest dose of nicotine (0.4 mg/kg). Therefore the next to 
the highest dose was selected for dSAT testing (0.1 mg/kg). Furthermore, this 
dose was previously shown to enhance attentional performance in the presence 
of bursts of white noise. (Hahn, Shoaib, & Stolerman, 2002).  However, we did 
not find any main effects of dose (all p>0.59) and no interactions between the 
effects of nicotine and block of trials on any measure of performance (4.2c; all 
p>0.11). 
 
 
 
 
  123 
 
 
Figure 4.2 
Characterization of the effects of distractor presentation on performance: (A) 
depicts the relative number of Hits for all for all three signal durations and across 
the three blocks of trials.  The Hit rate to longest, but not shortest, signals 
recovered partly during the post-distractor block of trials.  In contrast, CR 
recovered completely (B).  Shown in (C), the nicotine did not affect dSAT 
performance.  (D) Administration of S 38232 benefited the Hit rate during the 
post-distractor block of trials.   
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nAChR agonist-evoked cholinergic transients 
 
 We previously demonstrated that nAChR agonists evoke transient 
increases in acetylcholine (ACh) release in the prefrontal cortex and identified 
major aspects of the underlying neuronal mechanisms. This evidence supports 
the hypothesis that the greater pro-attentional efficacy of selective α4β2 nAChR 
agonists is related to their ability to evoke large and "sharp" cholinergic transients 
in contrast to nicotine (Parikh, et al., 2008; Sarter, Parikh, et al., 2009). Thus, we 
determined the cholinergic transients evoked by S 38232 and compared their 
amplitudes and decay rates with those evoked by nicotine. 
  The choline-sensitive microelectrodes used in these experiments were 
characterized by a sensitivity of 8.57±1.40 pA/µM, and a selectivity ratio for 
choline of relative to ascorbic acid. Administration of S 38232 (40, 200, 2000 
pmol) evoked cholinergic transients that were characterized by dose-dependent 
increases in amplitude (F(2,13)=29.05; p<0.001; post hoc LSDs indicated that 
the amplitude after the two higher doses was larger than those evoked by 40 
pmol; Figure 4.3a and d). Consistent with the classification of S 38232 as a 
selective α4β2* nAChR agonist, the amplitude of the cholinergic transient evoked 
by S 38232 (2 nmol) was almost completely attenuated by co-administration of 
the relatively β2-selective antagonist DHβE (1.6 nmol; residual amplitude: 
1.43±0.19 μM; t(8)=192.81; p<0.001).  
 Compared with the amplitudes of cholinergic transients evoked by nicotine 
(40 and 200 pmol, 4 and 20 nmol; Parikh et al, 2008), S 38232 was significantly 
more potent than nicotine in evoking cholinergic transients (Figure 4.3a,d). 
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Comparisons between the amplitudes evoked by the two lower doses of S 38232 
indicated larger cholinergic signal amplitudes compared with the amplitudes 
evoked by identical doses of nicotine (40 pmol: t(8)=3.94; p=0.004; 200 pmol: 
t(8)=3.11; p=0.01). The amplitude produced by the highest dose of S 38232 
corresponded with that evoked by the highest dose of nicotine (20 nmol; p=0.59). 
As Illustrated in Figure 4.3d, amplitudes generally reached a plateau at 5.5-6 μM, 
indicating that the greater potency of the selective agonist was not associated 
with greater efficacy.  
 Cholinergic transients evoked by S 38232 were robustly ‘sharper’ than 
those evoked by nicotine. First, as illustrated in Figure 4.3c, dose of S 38232 did 
not affect the relatively short rise time of transients evoked by this compound 
(time from administration of the compound to peak amplitude; F(2,15)=0.15; 
p=0.858; 5.73±0.28 s).  In contrast, nicotine-evoked signals required robustly 
more time to reach peak amplitude, up to almost 30 s for the highest dose (note 
again that peak amplitudes did not differ between the highest dose of S 38232 
and nicotine; above). Even at the second dose, 200 pmol, nicotine-evoked 
signals were slower to reach peak amplitude (nicotine: 21.75 ± 7.60 s; S 38232: 
5.94±1.04 s; t(8)=2.62, p=0.03).  
 Second, as illustrated in Figure 4.3e, t50 values of cholinergic signals 
evoked by S 38232 remained below 10 s even after the highest dose, contrasting 
with nicotine-evoked signals that required to almost 70 s to decline by 50% from 
peak values after the highest dose.  Dose of S 38232 affected the time required 
for the amplitude of cholinergic transients to decrease by 50% from peak levels 
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(t50) (F(2,15)=4.14; p=0.041). However, post hoc LSDs revealed that this effect 
was due to a relatively small increase in t50 (about 2 s) after the administration of 
200 pmol when compared with the effects of the lower and higher dose (40 pmol 
and 2 nmol; Figure 4.3e). Even at the second dose, 200 pmol, nicotine-evoked 
signals were significantly slower to decay (t50; nicotine: 39.75±12.43 s; S 38232: 
9.95±0.72 s; t(8)=2.82; p=0.02).  Collectively, these results indicate that S 38232 
evokes cholinergic transients with greater potency when compared with nicotine, 
and that cholinergic signals evoked by S 38232 differ from those resulting from 
nicotine with regard to rise times and decay rates, yielding robustly ‘sharper’ 
cholinergic transients evoked by S 38232.   
 
 
 
 
 
 
 
 
 
 
 
 
  127 
 
 
Figure 4.3 
Transient increases in prefrontal acetylcholine release evoked by S 38232 and 
nicotine (the nicotine data are used for comparison and were adopted from 
(Parikh, et al., 2008)). (A,B) provides examples of individual traces evoked by S 
38232 (A) and nicotine (B)..  (C) The time required for transients to reach peak 
amplitude (‘rise time’). Note the relatively fast and stable rise times for S 38232 
compared to nicotine. (D) Peak amplitudes.  S 38232 was more potent, but not 
efficacious, than nicotine.  (E) Transients evoked by nicotine were relatively slow 
to return to baseline taking ~70 s to decrease by 50% of peak (t50).  In contrast, 
t50 values for S 38232 were flat, also taking less than 10 s. Taken together, S 
38232 evokes ‘sharper’ transients than nicotine.  
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Blockade of α7 nAChR ‘sharpens’ nicotine-evoked transients 
As illustrated in figure 4.4 b-e, nicotine-evoked cholinergic transients were 
characterized by slower rise times and decay rates when compared with those 
evoked by the selective α4β2 nAChR agonist.  We earlier observed that blockade 
of the α7 nAChR with MLA did not affect the amplitude of nicotine-evoked 
cholinergic transients, but partly attenuated the slow rise time and slow decay 
rate (Figure 4.4 b-e; these data were taken from Parikh et al., 2008 and 
integrated into figure 4.3 to provide a justification for the test of the effects of the 
co-administration of nicotine and MLA on dSAT performance). More recently, we 
determined the effects of nicotine in mice lacking the α7 nAChR and again found 
that the slow rise time and decay rate of nicotine-evoked cholinergic signals are 
partly mediated through the α7 nAChR (Parikh, et al., 2010).  Thus, with respect 
to cholinergic transients, blocking the α7 nAChR converts nicotine into a more 
selective α4β2 nAChR agonist. 
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Figure 4.4 
Effect of MLA on nicotine evoked cholinergic transients.  (B) Nicotine-evoked 
cholinergic transients are ‘sharpened’ by MLA.  (C) Blocking the α7 nAChR, by 
co-administration of MLA, shortened the rise time of nicotine-evoked cholinergic 
transients.  (D) Blocking the α7 nAChR did not reduce the amplitudes of nicotine-
evoked transients. (E) Co-administration of MLA accelerated the decay rate of 
nicotine-evoked cholinergic signals, reducing t50 values to close to those for the 
α4β2 selective agonist.   
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Co-administration of nicotine and MLA enhances dSAT performance 
 Compared with the administration of saline or nicotine (0.1mg/kg) alone, 
co-administration of this dose of nicotine and MLA (1.0 mg/kg) enhanced the 
relative number of hits during dSAT performance.  As indicated in the Methods, 
we also tested a higher dose of MLA (5.0 mg/kg); however, co-administration of 
nicotine and the higher dose of MLA impaired performance, likely reflecting non-
selective antagonist effects of MLA (Lopez-Hernandez, et al., 2009). Therefore, 
these data are not described. 
 Compared with vehicle and nicotine administered alone, the co-
administration of nicotine and MLA enhance the Hit rate across all three blocks of 
trials of dSAT performance (Figure 4.5b; main effect of treatment: F(2,16)=5.46; 
p=0.016).  Figure 4.5a shows the effects over blocks.  This figure suggests that 
the co-treatment increased Hits particularly robustly during the post-distractor 
block, as with S 38232, although the effect of treatment did not interact with the 
effect of block (p=0.18).  
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Figure 4.5 
 
Effect of nicotine  and MLA co-treatment.  Co-administration of nicotine 
(0.1mg/kg) and MLA (1.0 mg/kg) enhanced the Hit rate across all blocks of the 
dSAT test session (B).  Although (A) suggests that the beneficial effects of the 
co-treatment were most robust in the post-distractor recovery period, there was 
no treatment X block interaction.  Here we again demonstrate that nicotine 
administered alone does not significantly benefit dSAT performance.     
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Effects of S 38232 on the performance in signal trials that followed correct 
rejections or misses 
 
 This analysis was based on the following rationale. We previously 
demonstrated that the detection of signals requires a transient, second-based 
increase in prefrontal cholinergic transmission (Parikh, et al., 2007). More recent 
evidence indicates that such transients are evoked in Hits specifically if they 
follow non-signal trials that yielded a correct rejection or signal trials that yielded 
a Miss (and thus may be considered perceived non-signal trials).  Analyses of the 
joint probability of a Hit on signal trials and for these signal trials to follow CR or 
Misses were conducted to test the prediction that the increase in hits produced 
by S 38232 during the post-distractor block 3 was due primarily to hits in signal 
trials that involved cue independent and cue dependent processing. 
Administration of S 38232 significantly increased the joint probability for a Hit in 
signal trials if preceded by CR or Misses (see bar graph in Figure 4.6; t(9)=2.72; 
p=0.023). In contrast, treatment with S 38232 did not affect the joint probability 
for hits that were preceded by hits or false alarms (t(9)=1.03; p=0.33). 
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Figure 4.6 
 
Analysis of the joint probabilities for Hit trials during the post-distractor period 
where the beneficial effects of S 38232 were observed. Compared to 
performance under vehicle, S 38232 increased the joint probability for a Hit 
following either a CR or a Miss.  The joint probability for a Hit following another 
Hit or a False Alarm was not augmented. This evidence forms the prediction that 
nAChR agonist-evoked enhancement of attentional performance manifests 
primarily in terms of Hits in trials that require a shift from cue-independent to cue-
dependent processing. 
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DISCUSSION 
  
 The main results of the behavioral and electrochemical experiments 
described above indicate that administration of a selective α4β2 nAChR agonist, 
but not nicotine, facilitates attentional performance under taxing conditions. 
Furthermore, compared with nicotine, the α4β2 nAChR agonist was more potent 
in evoking cholinergic transients which were characterized by very rapid 
termination of release, yielding "sharp" spikes in cholinergic activity. The more 
slowly rising and decaying transients evoked by nicotine are ‘sharpened’ by 
blocking the a7 nAChR; accordingly, we found that co-administration of nicotine 
with MLA robustly increased the Hit rate of dSAT-performing animals.  Results 
from trial-sequence analyses indicated that the beneficial performance effects 
were due to an increase in Hits in (signal) trials that followed either CR or Misses. 
Combined, these findings are consistent with the hypothesis that such selective 
agonists are able to amplify without broadening such transients, and thereby 
benefit the detection of signals, or more specifically performance on signal trials 
requiring a shift from cue-independent processing, in attention tasks. The 
discussion below will focus on a) the lack of beneficial effects of nicotine, b) the 
cognitive and neuronal mechanisms underlying the attentional effects of the 
selective α4β2* nAChR agonist, c) the prediction of attentional enhancement 
based on the characteristics of nAChR agonist-evoked cholinergic transients, 
and d) the implication of these findings for strategies focusing on the treatment of 
the cognitive symptoms of a range of disorders.  
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 As noted in the Introduction, the demonstration of beneficial attentional 
effects of nicotine in healthy, non-smoking humans and intact animals has been 
less than straight forward and effect sizes have remained generally small. In 
healthy, non-smoking humans, nicotine most consistently enhanced measures of 
response speed but rarely produced robust increases in measures of cue 
detection; rather, faster responding was observed occasionally to be associated 
with fewer detections (Foulds, et al., 1996; Giessing, Thiel, Rosler, & Fink, 2006; 
Hahn, et al., 2007; Kleykamp, Jennings, Blank, & Eissenberg, 2005; Newhouse, 
et al., 2004; Sahakian, Jones, Levy, Gray, & Warburton, 1989; Thiel & Fink, 
2008). 
  In intact animals, acute administration of nicotine likewise decreased 
response times but less consistently affected detection rate (Blondel, Sanger, & 
Moser, 2000; Bushnell, Oshiro, & Padnos, 1997; Stewart, Burke, & Marrocco, 
2001; Turchi, Holley, & Sarter, 1995), and depended on specific task parameters 
(Mirza & Stolerman, 1998) or strain of animals (Mirza & Bright, 2001; Stolerman, 
Mirza, Hahn, & Shoaib, 2000). Thus, the present evidence, indicating the 
absence of beneficial effects on performance accuracy is largely consistent with 
the literature (note that response latency measures generated by the current task 
are uninformative because of the 2-s delay between event and lever 
presentation). Previous experiments showed that administration of nicotine (at 
the same dose used to assess dSAT performance) attenuated the detrimental 
effects of bursts of white noise on five-choice serial reaction time task 
performance (Hahn, et al., 2002). The distracter condition used in our task is 
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more efficacious, as indicated by near random lever selection during block 2, 
thereby possibly limiting the efficacy of any treatment to attenuate the acute 
effects of the distractor. Thus it was expected that block 2 performance remained 
unaffected by nicotine. However, nicotine also did not benefit post-distractor 
performance recovery. We will come back to discussing this negative finding 
further below in the context of nicotine-evoked cholinergic transients. 
 In contrast to nicotine, the selective α4β2* nAChR agonist robustly 
enhanced post-distractor dSAT performance. Although the evidence from studies 
in humans, including patients, and animal experiments remains limited, such 
ligands appear to produce more robust attentional effects than nicotine (Dunbar, 
et al., 2007; Grottick & Higgins, 2000; McGaughy, et al., 1999; Wilens, et al., 
1999; Wilens & Decker, 2007; Wilens, et al., 2006). Our evidence further 
indicates that the performance-enhancing effects of the α4β2 nAChR agonist 
were due to an increase in detection rate (or Hits) and that the increase in Hits 
was found to occur in trial sequences that involved a shift from cue independent 
(no signal, response selection guided by propositional rules) to cue dependent 
attention (signal controls response selection in accordance with task rules). A 
neurobiological explanation of the superior efficacy of α4β2 nAChR agonists over 
nicotine will be offered further below, and this explanation predicts that the 
beneficial effects of α4β2* nAChR agonists are due to enhancing such shifts. The 
detection of signals, specifically if involving a shift from cue-independent to cue-
dependent attention, requires transient increases in cholinergic activity in 
prefrontal cortex. Ideally, the effects of nicotine and α4β2* selective nAChR 
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agonists on such transients, recorded in performing animals, would be expected 
to reveal the basis for their differential efficacy. Unfortunately, such studies 
remain extremely technically challenging. However, the limited evidence 
available from such studies indicates that the properties of cholinergic transients 
evoked by local administration of nAChR ligands in anesthetized animals 
generalize to the augmentation of transients recorded in performing animals 
(Gietzen, 2010). Our electrochemical studies indicated that such transients are a 
product of local prefrontal glutamatergic-cholinergic interactions (Parikh, et al., 
2008) mirroring the conclusions from prior psychopharmacological studies 
(Quarta, et al., 2007). Furthermore, α4β2* nAChRs control the amplitude of these 
transients; largely based on stimulation of such receptors situated on the 
glutamatergic terminals of thalamic afferents (Gioanni, et al., 1999). Resulting in 
stimulation of ionotropic glutamate receptors that may be directly located on the 
terminals of cholinergic afferents (Sarter, Parikh, et al., 2009). This model 
predicts, as indicated by the current data, that α4β2* nAChR agonists potently 
evoke, in terms of amplitude, cholinergic transients. Our prior data also suggest 
that the slow decay rate of nicotine-evoked cholinergic transients is indicative of 
ongoing and slowly diminishing acetylcholine release, is unrelated to effects 
mediated via α4β2* nAChRs, but are due, in part, to stimulation of α7 nAChR. 
Notably, the decay rate of atttentional performance mediating cholinergic 
transients corresponds with those evoked by α4β2* nAChR agonists, but not 
nicotine (Parikh, et al., 2007; Parikh, et al., 2008).  
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 Taken together, this evidence suggests the hypothesis that α4β2* nAChR 
agonists potently evoke "sharp" cholinergic transients and are more efficacious in 
enhancing cue detection and associated shifts between attention modes than 
agonists that evoke more lasting increases in release. Consistent with this 
hypothesis, we recently found that stimulation of α7 nAChRs produced extremely 
long-lasting increases in ACh release (Paolone, 2010) but, similar to experiments 
on the attentional effects of other α7 nAChR agonists (Grottick, Haman, Wyler, & 
Higgins, 2003; Grottick & Higgins, 2000; Hahn, Sharples, Wonnacott, Shoaib, & 
Stolerman, 2003) failed to benefit attentional performance. Thus, nicotine binding 
at receptors other than α4β2 nAChRs may interfere with the enhancing effects 
that result from stimulation of α4β2 nAChR. The attentional enhancement 
produced by selective α4β2 nAChR agonists is closely related to the "sharpness" 
of the cholinergic transients evoked by such compounds, combined with their 
greater potency in terms of the amplitudes of the cholinergic transients. The 
detrimental significance of lasting increases in ACh release can also be 
illustrated on the basis of the time scale at which shifts from cue-independent to 
cue-dependent attention occur in this task. Such a mode shift is triggered by the 
insertion of a preattentionally processed cue into prefrontal circuitry, fostering 
effective cue detection by this circuit (Sarter, Parikh, et al., 2009).  The 
occurrence of such a mode shift is evidenced by subsequent detection, or a hit, 
and it occurs within ~3 s after cue presentation. Thus, if nAChR agonists benefit 
performance by augmenting detection- and mode shift mediating cholinergic 
transients (Gietzen, 2010), it would be extremely difficult to conceptualize the 
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benefits of increases in ACh release that last for 30-70 s in the case of nicotine or 
tens of minutes in the case of α7 nAChR agonists (Paolone, 2010). The 
usefulness of the present behavioral and electrochemical approaches for basic 
research and drug development research deserve comment.  
 Consistent with the neurobiological conceptualization, the finding that the 
beneficial effects of the α4β2* nAChR agonist are due to the facilitation of 
attention mode shifts confirms the importance of the randomized sequencing of 
signal and explicit non-signal trials that differentiates the present task from other 
attention tasks. Second, the focus on dSAT performance over performance in the 
SAT is of clinical relevance as, for example, the attentional deficits of 
schizophrenic patients manifest primarily in the context of challenges to 
performance (Nuechterlein, et al., 2009; Sarter, Martinez, & Kozak, 2009). Such 
challenges further activate prefrontal circuitry, in part due to greater cholinergic 
activity as indicated by our prior experiments using microdialysis (Kozak, et al., 
2006). Treatment effects are expected to occur primarily during the recovery 
period, in part due to the tremendous efficacy of the distractor, but also while 
mechanisms are activated in order to recover attentional performance (Sarter, et 
al., 2006). Such effects may allow more defined interpretation than effects 
against an acute distractor, particularly in terms of predicting the potential 
usefulness of a drug for treating attentional impairments which, in most groups of 
patients with neuropsychiatric and neurodegenerative disorders or brain injury, 
are a function of the demands on effort and top-down control (Stulemeijer, 
Andriessen, Brauer, Vos, & Van Der Werf, 2007). 
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 Finally, the current evidence, combined with our prior work (Parikh, et al., 
2008), further suggests that characterizing the properties of cholinergic transients 
may serve as a useful neuropharmacological screening procedure for nAChR 
agonists. Although it will be necessary to further demonstrate that the amplitudes 
and decay rates of such transients predict the characteristics of the augmentation 
of such transients in performing animals (Gietzen, 2010), the present results 
substantiate the hypothesis that compounds which potently evoke second-based 
increases in ACh release benefit attentional performance more robustly than 
compounds that less potently increase ACh release and produce much longer 
lasting (minutes) release events. The present evidence indicates that nAChR 
mediated cholinergic activity in the cortex controls shifts in attention modes 
(Greenwood, Lin, Sundararajan, Fryxell, & Parasuraman, 2009) and that α4β2* 
nAChR agonists benefit attentional performance by enhancing the efficacy of 
shifts from cue-independent to cue-dependent attention. Impairments in the 
ability to disengage from endogenously-guided attention and allowing attention to 
be controlled by behaviorally significant stimuli, often termed "inattention", are 
essential elements of the cognitive symptoms of major disorders, including 
ADHD, age-related cognitive disorders, and schizophrenia. The evidence 
described above suggests therapeutic efficacy of α4β2* nAChR agonists for the 
cognitive symptoms of such disorders. 
 
 
 
 
 
 
  141 
References 
 
Apparsundaram, S., Martinez, V., Parikh, V., Kozak, R., & Sarter, M. (2005). 
Increased capacity and density of choline transporters situated in synaptic 
membranes of the right medial prefrontal cortex of attentional task-
performing rats. J Neurosci, 25(15), 3851-3856. 
Armstrong, D. M., Saper, C. B., Levey, A. I., Wainer, B. H., & Terry, R. D. (1983). 
Distribution of cholinergic neurons in rat brain: demonstrated by the 
immunocytochemical localization of choline acetyltransferase. J Comp 
Neurol, 216(1), 53-68. 
Arnold, H. M., Burk, J. A., Hodgson, E. M., Sarter, M., & Bruno, J. P. (2002). 
Differential cortical acetylcholine release in rats performing a sustained 
attention task versus behavioral control tasks that do not explicitly tax 
attention. Neuroscience, 114(2), 451-460. 
Arrington, C. M., Carr, T. H., Mayer, A. R., & Rao, S. M. (2000). Neural 
mechanisms of visual attention: object-based selection of a region in 
space. J Cogn Neurosci, 12 Suppl 2, 106-117. 
Bandyopadhyay, S., Sutor, B., & Hablitz, J. J. (2006). Endogenous acetylcholine 
enhances synchronized interneuron activity in rat neocortex. J 
Neurophysiol, 95(3), 1908-1916. 
Bartus, R. T., Dean, R. L., 3rd, Beer, B., & Lippa, A. S. (1982). The cholinergic 
hypothesis of geriatric memory dysfunction. Science, 217(4558), 408-414. 
Berg, D. K., & Conroy, W. G. (2002). Nicotinic alpha 7 receptors: synaptic options 
and downstream signaling in neurons. J Neurobiol, 53(4), 512-523. 
Blondel, A., Sanger, D. J., & Moser, P. C. (2000). Characterisation of the effects 
of nicotine in the five-choice serial reaction time task in rats: antagonist 
studies. Psychopharmacology (Berl), 149(3), 293-305. 
Book, A. A., Wiley, R. G., & Schweitzer, J. B. (1992). Specificity of 192 IgG-
saporin for NGF receptor-positive cholinergic basal forebrain neurons in 
the rat. Brain Res, 590(1-2), 350-355. 
Broussard, J. I., Karelina, K., Sarter, M., & Givens, B. (2009). Cholinergic 
optimization of cue-evoked parietal activity during challenged attentional 
performance. Eur J Neurosci, 29(8), 1711-1722. 
Burgess, P. W., Dumontheil, I., & Gilbert, S. J. (2007). The gateway hypothesis 
of rostral prefrontal cortex (area 10) function. Trends Cogn Sci, 11(7), 290-
298. 
Burgess, P. W., Veitch, E., de Lacy Costello, A., & Shallice, T. (2000). The 
cognitive and neuroanatomical correlates of multitasking. 
Neuropsychologia, 38(6), 848-863. 
  142 
Bushnell, P. J., Oshiro, W. M., & Padnos, B. K. (1997). Detection of visual signals 
by rats: effects of chlordiazepoxide and cholinergic and adrenergic drugs 
on sustained attention. Psychopharmacology (Berl), 134(3), 230-241. 
Cools, R., Rogers, R., Barker, R. A., & Robbins, T. W. (2010). Top-down 
attentional control in Parkinson's disease: salient considerations. J Cogn 
Neurosci, 22(5), 848-859. 
Corbetta, M., Kincade, J. M., Ollinger, J. M., McAvoy, M. P., & Shulman, G. L. 
(2000). Voluntary orienting is dissociated from target detection in human 
posterior parietal cortex. Nat Neurosci, 3(3), 292-297. 
Crick, F. (1984). Function of the thalamic reticular complex: the searchlight 
hypothesis. Proc Natl Acad Sci U S A, 81(14), 4586-4590. 
Dajas-Bailador, F., & Wonnacott, S. (2004). Nicotinic acetylcholine receptors and 
the regulation of neuronal signalling. Trends Pharmacol Sci, 25(6), 317-
324. 
Demeter, E., Hernandez-Garcia, L., Sarter, M., & Lustig, C. (2011). Challenges to 
attention: a continuous arterial spin labeling (ASL) study of the effects of 
distraction on sustained attention. Neuroimage, 54(2), 1518-1529. 
Demeter, E., Sarter, M., & Lustig, C. (2008). Rats and humans paying attention: 
cross-species task development for translational research. 
Neuropsychology, 22(6), 787-799. 
Deutsch, J. A. (1971). The cholinergic synapse and the site of memory. Science, 
174(11), 788-794. 
Dickinson, J. A., Kew, J. N., & Wonnacott, S. (2008). Presynaptic alpha 7- and 
beta 2-containing nicotinic acetylcholine receptors modulate excitatory 
amino acid release from rat prefrontal cortex nerve terminals via distinct 
cellular mechanisms. Mol Pharmacol, 74(2), 348-359. 
Disney, A. A., & Aoki, C. (2008). Muscarinic acetylcholine receptors in macaque 
V1 are most frequently expressed by parvalbumin-immunoreactive 
neurons. J Comp Neurol, 507(5), 1748-1762. 
Dunbar, G. C., Inglis, F., Kuchibhatla, R., Sharma, T., Tomlinson, M., & Wamsley, 
J. (2007). Effect of ispronicline, a neuronal nicotinic acetylcholine receptor 
partial agonist, in subjects with age associated memory impairment 
(AAMI). J Psychopharmacol, 21(2), 171-178. 
Everitt, B. J., & Robbins, T. W. (1997). Central cholinergic systems and cognition. 
Annu Rev Psychol, 48, 649-684. 
Foulds, J., Stapleton, J., Swettenham, J., Bell, N., McSorley, K., & Russell, M. A. 
(1996). Cognitive performance effects of subcutaneous nicotine in 
smokers and never-smokers. Psychopharmacology (Berl), 127(1), 31-38. 
Fransen, E., Alonso, A. A., & Hasselmo, M. E. (2002). Simulations of the role of 
the muscarinic-activated calcium-sensitive nonspecific cation current 
  143 
INCM in entorhinal neuronal activity during delayed matching tasks. J 
Neurosci, 22(3), 1081-1097. 
Freedman, R., Olincy, A., Buchanan, R. W., Harris, J. G., Gold, J. M., Johnson, 
L., et al. (2008). Initial phase 2 trial of a nicotinic agonist in schizophrenia. 
Am J Psychiatry, 165(8), 1040-1047. 
Frey, P., Colliver, J. (1973). Sensitivity and responsivity measures for 
discrimination learning. Learning and Motivation, 4(3), 327-342. 
Galzi, J. L., & Changeux, J. P. (1995). Neuronal nicotinic receptors: molecular 
organization and regulations. Neuropharmacology, 34(6), 563-582. 
Galzi, J. L., Edelstein, S. J., & Changeux, J. (1996). The multiple phenotypes of 
allosteric receptor mutants. Proc Natl Acad Sci U S A, 93(5), 1853-1858. 
Giessing, C., Thiel, C. M., Rosler, F., & Fink, G. R. (2006). The modulatory 
effects of nicotine on parietal cortex activity in a cued target detection task 
depend on cue reliability. Neuroscience, 137(3), 853-864. 
Gietzen, J., Howe, W.M., Decker, M.,  Sarter, M. (2010). Modulation of 
cholinergic transients mediating cue detection and detection performance  
Paper presented at the Society For Neuroscience San Diego, CA. 
Gioanni, Y., Rougeot, C., Clarke, P. B., Lepouse, C., Thierry, A. M., & Vidal, C. 
(1999). Nicotinic receptors in the rat prefrontal cortex: increase in 
glutamate release and facilitation of mediodorsal thalamo-cortical 
transmission. Eur J Neurosci, 11(1), 18-30. 
Goard, M., & Dan, Y. (2009). Basal forebrain activation enhances cortical coding 
of natural scenes. Nat Neurosci, 12(11), 1444-1449. 
Greenwood, P. M., Lin, M. K., Sundararajan, R., Fryxell, K. J., & Parasuraman, R. 
(2009). Synergistic effects of genetic variation in nicotinic and muscarinic 
receptors on visual attention but not working memory. Proc Natl Acad Sci 
U S A, 106(9), 3633-3638. 
Grottick, A. J., Haman, M., Wyler, R., & Higgins, G. A. (2003). Reversal of a 
vigilance decrement in the aged rat by subtype-selective nicotinic ligands. 
Neuropsychopharmacology, 28(5), 880-887. 
Grottick, A. J., & Higgins, G. A. (2000). Effect of subtype selective nicotinic 
compounds on attention as assessed by the five-choice serial reaction 
time task. Behav Brain Res, 117(1-2), 197-208. 
Hagan, J. J., & Jones, D. N. (2005). Predicting drug efficacy for cognitive deficits 
in schizophrenia. Schizophr Bull, 31(4), 830-853. 
Hahn, B., Ross, T. J., Yang, Y., Kim, I., Huestis, M. A., & Stein, E. A. (2007). 
Nicotine enhances visuospatial attention by deactivating areas of the 
resting brain default network. J Neurosci, 27(13), 3477-3489. 
  144 
Hahn, B., Sharples, C. G., Wonnacott, S., Shoaib, M., & Stolerman, I. P. (2003). 
Attentional effects of nicotinic agonists in rats. Neuropharmacology, 44(8), 
1054-1067. 
Hahn, B., Shoaib, M., & Stolerman, I. P. (2002). Nicotine-induced enhancement 
of attention in the five-choice serial reaction time task: the influence of task 
demands. Psychopharmacology (Berl), 162(2), 129-137. 
Hasselmo, M. E., & Barkai, E. (1995). Cholinergic modulation of activity-
dependent synaptic plasticity in the piriform cortex and associative 
memory function in a network biophysical simulation. J Neurosci, 15(10), 
6592-6604. 
Hasselmo, M. E., & Bower, J. M. (1992). Cholinergic suppression specific to 
intrinsic not afferent fiber synapses in rat piriform (olfactory) cortex. J 
Neurophysiol, 67(5), 1222-1229. 
Hasselmo, M. E., & McGaughy, J. (2004). High acetylcholine levels set circuit 
dynamics for attention and encoding and low acetylcholine levels set 
dynamics for consolidation. Prog Brain Res, 145, 207-231. 
Hasselmo, M. E., & Sarter, M. (2010). Modes and models of forebrain cholinergic 
neuromodulation of cognition. Neuropsychopharmacology, 36(1), 52-73. 
Hasselmo, M. E., & Stern, C. E. (2006). Mechanisms underlying working memory 
for novel information. Trends Cogn Sci, 10(11), 487-493. 
Henseler, I., Kruger, S., Dechent, P., & Gruber, O. A gateway system in rostral 
PFC? Evidence from biasing attention to perceptual information and 
internal representations. Neuroimage, 56(3), 1666-1676. 
Himmelheber, A. M., Sarter, M., & Bruno, J. P. (2001). The effects of 
manipulations of attentional demand on cortical acetylcholine release. 
Brain Res Cogn Brain Res, 12(3), 353-370. 
Howell, D. (1989). Fundamental Statistics for Behavioral Sciences. Boston, MA: 
PWS-Kent Publishing Company. 
Huerta, P. T., & Lisman, J. E. (1993). Heightened synaptic plasticity of 
hippocampal CA1 neurons during a cholinergically induced rhythmic state. 
Nature, 364(6439), 723-725. 
Johnston, K., Levin, H. M., Koval, M. J., & Everling, S. (2007). Top-down control-
signal dynamics in anterior cingulate and prefrontal cortex neurons 
following task switching. Neuron, 53(3), 453-462. 
Kleykamp, B. A., Jennings, J. M., Blank, M. D., & Eissenberg, T. (2005). The 
effects of nicotine on attention and working memory in never-smokers. 
Psychol Addict Behav, 19(4), 433-438. 
Kozak, R., Bruno, J. P., & Sarter, M. (2006). Augmented prefrontal acetylcholine 
release during challenged attentional performance. Cereb Cortex, 16(1), 
9-17. 
  145 
Lagostena, L., Danober, L., Challal, S., Lestage, P., Mocaer, E., Trocme-
Thibierge, C., et al. (2010). Modulatory effects of S 38232, a non alpha-7 
containing nicotine acetylcholine receptor agonist on network activity in 
the mouse hippocampus. Neuropharmacology, 58(4-5), 806-815. 
Lambe, E. K., Picciotto, M. R., & Aghajanian, G. K. (2003). Nicotine induces 
glutamate release from thalamocortical terminals in prefrontal cortex. 
Neuropsychopharmacology, 28(2), 216-225. 
Laurens, K. R., Kiehl, K. A., Ngan, E. T., & Liddle, P. F. (2005). Attention 
orienting dysfunction during salient novel stimulus processing in 
schizophrenia. Schizophr Res, 75(2-3), 159-171. 
Lippiello, P., Letchworth, S. R., Gatto, G. J., Traina, V. M., & Bencherif, M. (2006). 
Ispronicline: a novel alpha4beta2 nicotinic acetylcholine receptor-selective 
agonist with cognition-enhancing and neuroprotective properties. J Mol 
Neurosci, 30(1-2), 19-20. 
Lopez-Hernandez, G. Y., Thinschmidt, J. S., Zheng, G., Zhang, Z., Crooks, P. A., 
Dwoskin, L. P., et al. (2009). Selective inhibition of acetylcholine-evoked 
responses of alpha7 neuronal nicotinic acetylcholine receptors by novel 
tris- and tetrakis-azaaromatic quaternary ammonium antagonists. Mol 
Pharmacol, 76(3), 652-666. 
Luiten, P. G., Gaykema, R. P., Traber, J., & Spencer, D. G., Jr. (1987). Cortical 
projection patterns of magnocellular basal nucleus subdivisions as 
revealed by anterogradely transported Phaseolus vulgaris leucoagglutinin. 
Brain Res, 413(2), 229-250. 
Lustig, C., Berry, A., Howe, W., Sarter, M. (2011). Attention processing-mode 
switches: Cross-species research linking cholinergic transients and BOLD 
activations in the switch from endogenous to exogenous attention. Paper 
presented at the Annual Meeting of the Society for Neuroscience, 
Washington, D.C. 
Lysakowski, A., Wainer, B. H., Bruce, G., & Hersh, L. B. (1989). An atlas of the 
regional and laminar distribution of choline acetyltransferase 
immunoreactivity in rat cerebral cortex. Neuroscience, 28(2), 291-336. 
Martinez, V., & Sarter, M. (2004). Lateralized attentional functions of cortical 
cholinergic inputs. Behav Neurosci, 118(5), 984-991. 
McCaig, R. G., Dixon, M., Keramatian, K., Liu, I., & Christoff, K. Improved 
modulation of rostrolateral prefrontal cortex using real-time fMRI training 
and meta-cognitive awareness. Neuroimage, 55(3), 1298-1305. 
McGaughy, J., Dalley, J. W., Morrison, C. H., Everitt, B. J., & Robbins, T. W. 
(2002). Selective behavioral and neurochemical effects of cholinergic 
lesions produced by intrabasalis infusions of 192 IgG-saporin on 
attentional performance in a five-choice serial reaction time task. J 
Neurosci, 22(5), 1905-1913. 
  146 
McGaughy, J., Decker, M. W., & Sarter, M. (1999). Enhancement of sustained 
attention performance by the nicotinic acetylcholine receptor agonist ABT-
418 in intact but not basal forebrain-lesioned rats. Psychopharmacology 
(Berl), 144(2), 175-182. 
McGaughy, J., Kaiser, T., & Sarter, M. (1996). Behavioral vigilance following 
infusions of 192 IgG-saporin into the basal forebrain: selectivity of the 
behavioral impairment and relation to cortical AChE-positive fiber density. 
Behav Neurosci, 110(2), 247-265. 
McGaughy, J., & Sarter, M. (1995). Behavioral vigilance in rats: task validation 
and effects of age, amphetamine, and benzodiazepine receptor ligands. 
Psychopharmacology (Berl), 117(3), 340-357. 
Mesulam, M. M., Mufson, E. J., Wainer, B. H., & Levey, A. I. (1983). Central 
cholinergic pathways in the rat: an overview based on an alternative 
nomenclature (Ch1-Ch6). Neuroscience, 10(4), 1185-1201. 
Metherate, R., & Ashe, J. H. (1991). Basal forebrain stimulation modifies auditory 
cortex responsiveness by an action at muscarinic receptors. Brain Res, 
559(1), 163-167. 
Metherate, R., & Ashe, J. H. (1993). Nucleus basalis stimulation facilitates 
thalamocortical synaptic transmission in the rat auditory cortex. Synapse, 
14(2), 132-143. 
Metherate, R., Ashe, J. H., & Weinberger, N. M. (1990). Acetylcholine modifies 
neuronal acoustic rate-level functions in guinea pig auditory cortex by an 
action at muscarinic receptors. Synapse, 6(4), 364-368. 
Metherate, R., & Weinberger, N. M. (1989). Acetylcholine produces stimulus-
specific receptive field alterations in cat auditory cortex. Brain Res, 480(1-
2), 372-377. 
Metherate, R., & Weinberger, N. M. (1990). Cholinergic modulation of responses 
to single tones produces tone-specific receptive field alterations in cat 
auditory cortex. Synapse, 6(2), 133-145. 
Mirza, N. R., & Bright, J. L. (2001). Nicotine-induced enhancements in the five-
choice serial reaction time task in rats are strain-dependent. 
Psychopharmacology (Berl), 154(1), 8-12. 
Mirza, N. R., & Stolerman, I. P. (1998). Nicotine enhances sustained attention in 
the rat under specific task conditions. Psychopharmacology (Berl), 138(3-
4), 266-274. 
Mrzljak, L., & Goldman-Rakic, P. S. (1992). Acetylcholinesterase reactivity in the 
frontal cortex of human and monkey: contribution of AChE-rich pyramidal 
neurons. J Comp Neurol, 324(2), 261-281. 
Mrzljak, L., & Goldman-Rakic, P. S. (1993). Low-affinity nerve growth factor 
receptor (p75NGFR)- and choline acetyltransferase (ChAT)-
  147 
immunoreactive axons in the cerebral cortex and hippocampus of adult 
macaque monkeys and humans. Cereb Cortex, 3(2), 133-147. 
Mrzljak, L., Levey, A. I., & Goldman-Rakic, P. S. (1993). Association of m1 and 
m2 muscarinic receptor proteins with asymmetric synapses in the primate 
cerebral cortex: morphological evidence for cholinergic modulation of 
excitatory neurotransmission. Proc Natl Acad Sci U S A, 90(11), 5194-
5198. 
Mrzljak, L., Pappy, M., Leranth, C., & Goldman-Rakic, P. S. (1995). Cholinergic 
synaptic circuitry in the macaque prefrontal cortex. J Comp Neurol, 357(4), 
603-617. 
Munk, M. H., Roelfsema, P. R., Konig, P., Engel, A. K., & Singer, W. (1996). Role 
of reticular activation in the modulation of intracortical synchronization. 
Science, 272(5259), 271-274. 
Newhouse, P. A., Potter, A., & Singh, A. (2004). Effects of nicotinic stimulation on 
cognitive performance. Curr Opin Pharmacol, 4(1), 36-46. 
Nuechterlein, K. H., Luck, S. J., Lustig, C., & Sarter, M. (2009). CNTRICS final 
task selection: control of attention. Schizophr Bull, 35(1), 182-196. 
Paolone, G., Howe, M.W., Gopalakrishnan, M., Decker, M.W., & Sarter M. (2010). 
Regulation and function of the tonic component of cortical acetylcholine 
release. Paper presented at the Monitoring Molecules in Neuroscience, 
Vrije Universiteit Brussel, Brussels, Belgium. 
Parasuraman, R., Warm, J.S., & Dember W.N. (1987). Vigilance: taxonomy and 
utility. . In J. S. W. L.S. Mark, & R.L. Huston (Ed.), Ergonomics and human 
factors (pp. 11-32). New York: Springer. 
Parikh, V., Ji, J., Decker, M. W., & Sarter, M. (2010). Prefrontal beta2 subunit-
containing and alpha7 nicotinic acetylcholine receptors differentially 
control glutamatergic and cholinergic signaling. J Neurosci, 30(9), 3518-
3530. 
Parikh, V., Kozak, R., Martinez, V., & Sarter, M. (2007). Prefrontal acetylcholine 
release controls cue detection on multiple timescales. Neuron, 56(1), 141-
154. 
Parikh, V., Man, K., Decker, M. W., & Sarter, M. (2008). Glutamatergic 
contributions to nicotinic acetylcholine receptor agonist-evoked cholinergic 
transients in the prefrontal cortex. J Neurosci, 28(14), 3769-3780. 
Parikh, V., Pomerleau, F., Huettl, P., Gerhardt, G. A., Sarter, M., & Bruno, J. P. 
(2004). Rapid assessment of in vivo cholinergic transmission by 
amperometric detection of changes in extracellular choline levels. Eur J 
Neurosci, 20(6), 1545-1554. 
Posner, M. I., Snyder, C. R., & Davidson, B. J. (1980). Attention and the 
detection of signals. J Exp Psychol, 109(2), 160-174. 
  148 
Potter, A., Corwin, J., Lang, J., Piasecki, M., Lenox, R., & Newhouse, P. A. 
(1999). Acute effects of the selective cholinergic channel activator 
(nicotinic agonist) ABT-418 in Alzheimer's disease. Psychopharmacology 
(Berl), 142(4), 334-342. 
Prendergast, M. A., Jackson, W. J., Terry, A. V., Jr., Decker, M. W., Arneric, S. 
P., & Buccafusco, J. J. (1998). Central nicotinic receptor agonists ABT-
418, ABT-089, and (-)-nicotine reduce distractibility in adult monkeys. 
Psychopharmacology (Berl), 136(1), 50-58. 
Quarta, D., Naylor, C. G., Morris, H. V., Patel, S., Genn, R. F., & Stolerman, I. P. 
(2007). Different effects of ionotropic and metabotropic glutamate receptor 
antagonists on attention and the attentional properties of nicotine. 
Neuropharmacology, 53(3), 421-430. 
Rotter, A., & Jacobwitz, D. M. (1981). Neurochemical identification of cholinergic 
forebrain projection sites of the nucleus tegmentalis dorsalis lateralis. 
Brain Res Bull, 6(6), 525-529. 
Rye, D. B., Saper, C. B., Lee, H. J., & Wainer, B. H. (1987). Pedunculopontine 
tegmental nucleus of the rat: cytoarchitecture, cytochemistry, and some 
extrapyramidal connections of the mesopontine tegmentum. J Comp 
Neurol, 259(4), 483-528. 
Sahakian, B., Jones, G., Levy, R., Gray, J., & Warburton, D. (1989). The effects 
of nicotine on attention, information processing, and short-term memory in 
patients with dementia of the Alzheimer type. Br J Psychiatry, 154, 797-
800. 
Sarter, M. (1991). Taking stock of cognition enhancers. Trends Pharmacol Sci, 
12(12), 456-461. 
Sarter, M. (2006). Preclinical research into cognition enhancers. Trends 
Pharmacol Sci, 27(11), 602-608. 
Sarter, M., Gehring, W. J., & Kozak, R. (2006). More attention must be paid: the 
neurobiology of attentional effort. Brain Res Rev, 51(2), 145-160. 
Sarter, M., Hagan, J., & Dudchenko, P. (1992a). Behavioral screening for 
cognition enhancers: from indiscriminate to valid testing: Part I. 
Psychopharmacology (Berl), 107(2-3), 144-159. 
Sarter, M., Hagan, J., & Dudchenko, P. (1992b). Behavioral screening for 
cognition enhancers: from indiscriminate to valid testing: Part II. 
Psychopharmacology (Berl), 107(4), 461-473. 
Sarter, M., Hasselmo, M. E., Bruno, J. P., & Givens, B. (2005). Unraveling the 
attentional functions of cortical cholinergic inputs: interactions between 
signal-driven and cognitive modulation of signal detection. Brain Res Brain 
Res Rev, 48(1), 98-111. 
  149 
Sarter, M., Martinez, V., & Kozak, R. (2009). A neurocognitive animal model 
dissociating between acute illness and remission periods of schizophrenia. 
Psychopharmacology (Berl), 202(1-3), 237-258. 
Sarter, M., & Paolone, G. (2011). Deficits in attentional control: Cholinergic 
mechanisms and circuitry-based treatment approaches. Behav Neurosci, 
125(6), 825-835. 
Sarter, M., Parikh, V., & Howe, W. M. (2009). nAChR agonist-induced cognition 
enhancement: integration of cognitive and neuronal mechanisms. 
Biochem Pharmacol, 78(7), 658-667. 
Shulman, G. L., d'Avossa, G., Tansy, A. P., & Corbetta, M. (2002). Two 
attentional processes in the parietal lobe. Cereb Cortex, 12(11), 1124-
1131. 
St Peters, M., Demeter, E., Lustig, C., Bruno, J. P., & Sarter, M. (2011). 
Enhanced control of attention by stimulating mesolimbic-corticopetal 
cholinergic circuitry. J Neurosci, 31(26), 9760-9771. 
Stewart, C., Burke, S., & Marrocco, R. (2001). Cholinergic modulation of covert 
attention in the rat. Psychopharmacology (Berl), 155(2), 210-218. 
Stolerman, I. P., Mirza, N. R., Hahn, B., & Shoaib, M. (2000). Nicotine in an 
animal model of attention. Eur J Pharmacol, 393(1-3), 147-154. 
Stulemeijer, M., Andriessen, T. M., Brauer, J. M., Vos, P. E., & Van Der Werf, S. 
(2007). Cognitive performance after mild traumatic brain injury: the impact 
of poor effort on test results and its relation to distress, personality and 
litigation. Brain Inj, 21(3), 309-318. 
Tago, H., Kimura, H., & Maeda, T. (1986). Visualization of detailed 
acetylcholinesterase fiber and neuron staining in rat brain by a sensitive 
histochemical procedure. J Histochem Cytochem, 34(11), 1431-1438. 
Thiel, C. M., & Fink, G. R. (2008). Effects of the cholinergic agonist nicotine on 
reorienting of visual spatial attention and top-down attentional control. 
Neuroscience, 152(2), 381-390. 
Turchi, J., Holley, L. A., & Sarter, M. (1995). Effects of nicotinic acetylcholine 
receptor ligands on behavioral vigilance in rats. Psychopharmacology 
(Berl), 118(2), 195-205. 
Turchi, J., & Sarter, M. (1997). Cortical acetylcholine and processing capacity: 
effects of cortical cholinergic deafferentation on crossmodal divided 
attention in rats. Brain Res Cogn Brain Res, 6(2), 147-158. 
Volle, E., Gonen-Yaacovi, G., Costello Ade, L., Gilbert, S. J., & Burgess, P. W. 
The role of rostral prefrontal cortex in prospective memory: a voxel-based 
lesion study. Neuropsychologia, 49(8), 2185-2198. 
Weinberger, N. M. (2003). The nucleus basalis and memory codes: auditory 
cortical plasticity and the induction of specific, associative behavioral 
memory. Neurobiol Learn Mem, 80(3), 268-284. 
  150 
Weissman, D. H., Warner, L. M., & Woldorff, M. G. (2004). The neural 
mechanisms for minimizing cross-modal distraction. J Neurosci, 24(48), 
10941-10949. 
Wilens, T. E., Biederman, J., Spencer, T. J., Bostic, J., Prince, J., Monuteaux, M. 
C., et al. (1999). A pilot controlled clinical trial of ABT-418, a cholinergic 
agonist, in the treatment of adults with attention deficit hyperactivity 
disorder. Am J Psychiatry, 156(12), 1931-1937. 
Wilens, T. E., & Decker, M. W. (2007). Neuronal nicotinic receptor agonists for 
the treatment of attention-deficit/hyperactivity disorder: focus on cognition. 
Biochem Pharmacol, 74(8), 1212-1223. 
Wilens, T. E., Verlinden, M. H., Adler, L. A., Wozniak, P. J., & West, S. A. (2006). 
ABT-089, a neuronal nicotinic receptor partial agonist, for the treatment of 
attention-deficit/hyperactivity disorder in adults: results of a pilot study. Biol 
Psychiatry, 59(11), 1065-1070. 
Wiley, R. G., Oeltmann, T. N., & Lappi, D. A. (1991). Immunolesioning: selective 
destruction of neurons using immunotoxin to rat NGF receptor. Brain Res, 
562(1), 149-153. 
Witten, I. B., Steinberg, E. E., Lee, S. Y., Davidson, T. J., Zalocusky, K. A., 
Brodsky, M., et al. Recombinase-driver rat lines: tools, techniques, and 
optogenetic application to dopamine-mediated reinforcement. Neuron, 
72(5), 721-733. 
Wonnacott, S. (1997). Presynaptic nicotinic ACh receptors. Trends Neurosci, 
20(2), 92-98. 
Woolf, N. J., & Butcher, L. L. (1986). Cholinergic systems in the rat brain: III. 
Projections from the pontomesencephalic tegmentum to the thalamus, 
tectum, basal ganglia, and basal forebrain. Brain Res Bull, 16(5), 603-637. 
Woolf, N. J., Eckenstein, F., & Butcher, L. L. (1983). Cholinergic projections from 
the basal forebrain to the frontal cortex: a combined fluorescent tracer and 
immunohistochemical analysis in the rat. Neurosci Lett, 40(2), 93-98. 
Xiang, Z., Huguenard, J. R., & Prince, D. A. (1998). Cholinergic switching within 
neocortical inhibitory networks. Science, 281(5379), 985-988. 
 
 
 
 
 
 
  151 
Chapter V 
General discussion 
 
 
Synopsis 
 
The main goals of the experiments included in my dissertation were to 1) 
employ a novel technique capable of monitoring changes in cholinergic activity at 
a on a sub-second resolution in task performing animals to better understand the 
function of cholinergic signaling during attentional performance 2) to apply this 
high temporal resolution electrochemical technique to glutamate release in 
animals performing the same attention task to provide insight into the interaction 
between these two major neurotransmitter systems in the context of attentional 
performance 3) to demonstrate that by building upon our knowledge of the 
functions of and  interactions between these two systems, we can predict and 
explain why selective α4β2 nAChR agonists more robustly enhance attentional 
performance than the non-selective nAChR agonist nicotine.   
Disregulation of attentional processes plays a role in a host of 
psychological disorders from ADHD to schizophrenia. Attention is essential to 
learning and memory and gates all learning events. Understanding the 
mechanisms underlying attentional function is paramount to understanding their 
disorder in disease states and to creating cognitive enhancers.  
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The studies described here give robust support for the cholingeric 
system’s involvement in attentional processes. Acetylcholine is widely 
transmitted and therefore was not thought to be involved in discrete cognitive 
processes. The studies described here advance the understanding of the 
psychological function of the cholinergic system, affording it a role in specific 
attentional processes.  By demonstrating the interaction of choline and glutamate 
in cue detection, these studies also describe a neurobiological mechanism for 
this specificity of function.  This proposed mechanism can be tested by further 
hypothesis driven experiments and allow creation of compounds with putative 
cognition enhancing abilities.  
The previously described work demonstrates for the first time subsecond 
data on both acetylcholine and glutamate transmission. New techniques with 
faster rates of data acquisition that allow detection of the actual chemical signal 
advance the field and our understanding of neural function. They force new 
hypotheses to be created and tested. What follows is a summary of the major 
findings from each chapter as well a potential directions for future research to 
further clarify the results of the present studies.  
 
General Limitations 
 There are a few limitations to the studies described. The lesion studies 
described had a major caveat. Lesion of the cholinergic inputs to the prefrontal 
cortex destroyed both modes of cholinergic transmission, both tonic and phasic. 
Therefore we are unable to make strong conclusions about whether the deficits 
  153 
seen in those animals that received lesions were due to the lack of phasic or 
tonic acetylcholine. The electrochemical studies described also need expansion. 
First, all recording reported were made from layer V of the prefrontal cortex, the 
thalamic input layer. Transient cholinergic increases that underlie cue detection 
need sensory information from the thalamus, therefore these same transients 
would not be expected in other cortical layers. Recordings were not made from I 
and VI, which predominately receive information from other cortical areas. The 
currents findings would be strengthened if laminar specificity could be 
demonstrated.  Second, based on previous data that demonstrates depletion of 
right hemispheric cholinergic inputs impairs performance on Hit trials and SAT 
performance leads to an up regulation of choline transporter in the right 
hemisphere, I recorded choline release from the right hemisphere only. To more 
completely understand the function of the cholingeric system in attentional 
processes, both hemispheres need to be tested. Finally, only the prefrontal 
cortex was recorded from. Therefore, it is unknown if these transients are unique 
to the prefrontal cortex.  
 
Chapter 2 Summary 
 Previous experiments utilizing a selective cholinergic toxin to remove 
cholinergic inputs to the cortex, and preliminary experiments employing choline-
sensitive microelectrodes in animals performing a cued appetitive response task 
led us to hypothesize that in the SAT, detected cues on Hits would evoke 
increases in cholinergic neurotransmission in prefrontal regions, and that removal 
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of prefrontal cholinergic inputs would impair Hit performance (McGaughy, et al., 
1996; Parikh, et al., 2007). Here, we demonstrated that increases in cholinergic 
activity are only seen only on Hits, but only if that Hit is preceded by a CR or Miss. 
In accordance with the electrochemical data, removal of cholinergic input to the 
prefrontal cortex impaired performance on only on MissHit trial sequences.  
Because of the trial sequence-dependent occurrence of increases in cholinergic 
activity on hit trials, and the selective performance impairment following the 
lesion, our initial hypothesis concerning the role of cholinergic transients in 
mediating cue detection were revisited.   We have focused on two different 
possible explanations for the selectivity of cholinergic activity in the SAT, each of 
which places emphasis upon different parts of the cholinergic release event and 
neither is mutually exclusive of the other. The first is that cue-evoked increases in 
cholinergic activity mediate the shift between cue-independent to cue-dependent 
attention. This hypothesis focuses solely upon the trial sequence dependence of 
an evoked cholinergic signal, and particular attention is paid to the fact that levels 
of cholinergic activity are significantly elevated at the time the animals are 
prompted to make their response. The functional relevance of the remainder of 
the signal is not considered.  The second is that increases in cholinergic activity 
as a reporter or learning signal, and attempts to account for the sequence 
dependency, as well as the full time course of the release. The major assumption 
is that as choline levels continue to increase, ACh release and hydrolyzation 
must be ongoing, and this on-going release is functionally relevant to current or 
future performance.   
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Future Experiments, Chapter 2 
 We have begun to plan additional experiments to help clarify the function 
of these cholinergic transients.  The first addresses the selectivity of cholinergic 
transients for non-signalsignal trial sequences.  I have designed a “tracking” 
task where a cue light situated above each response lever indicates which must 
be pressed in order to receive reward and thus only signal trials exist. Non-signal 
trials have been engineered out of the task.  For continuity, I have kept as many 
of the parameters of this task consistent with the SAT as possible; the houselight 
remains on throughout the task, it includes a variable inter-trial interval of 9±3 s, 
variable stimulus durations (500, 50, 25 ms), and task length is set at 40 minutes.  
The hypothesis is that in this task, which involves no shifts from cue-independent 
to cue-dependent processing, detected cues will not evoke cholinergic transients.  
Further, prefrontal cholinergic deafferentation will not impair performance.   
 Clarifying whether cholinergic transients exclusively mediate the shift 
between cue-independent and cue-dependent processing, or also act as a 
learning signal, we have discussed two possible experiments.  The first is to 
lengthen the interval between the cue and the extension of the response levers.  
The prediction of the results requires some speculation.  If cholinergic transients 
act as a learning signal, it could be expected that cholinergic activity helps 
reinforce the association between signal-response-and reward. Under this 
hypothesis acetylcholine release begins to increase following the offset of the 
cue on, for example, a CRHit sequence.  Release would continue through the 
interval between cue and response lever, and as with the cholinergic transients in 
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the present study, continue to rise for following response and reward retrieval. In 
sum, the shape of the cholinergic transients described here would be broadened 
extending across the added time of the longer ITI. Note that in this instance the 
onset of the cholinergic transient begins with the cue, the first event in a chain of 
events (cueresponsereward) that are being associated.  A second possibility 
is that in a version of the SAT with a longer interval between the visual cue, the 
onset and peak of the transient might be right shifted to coincide with the timing 
of lever extension, response, and retrieval.  If the peak can be broadened or 
right-shifted, the transient could be interpreted as a learning signal as reward 
delivery acts as the final confirmation.  If cholinergic transients simply mediate 
the shift from cue independent to cue dependent processing, the transients in the 
version of the task with the lengthened interval would have the same 
characteristics as those in the current experiments as in either case it is the 
visual cue and the visual cue alone that is responsible for the cue-independent to 
cue-dependent attention shift.        
 A second approach could take advantage of (Chat)::Cre rats (Witten, et 
al.) and the ability to silence cholinergic release using the chloride pump 
Halorhodopsin during incongruent trial sequences.  If the cholinergic signal is 
mediating the shift between cue-independent and cue-dependent processing 
alone, then silencing cholinergic signaling should acutely impair performance and 
trials involving shifts.  Alternatively, if the cholinergic transient is a learning signal, 
performance would remain intact during the first incongruent sequences where 
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ACh release has been blocked, and decline slowly over time as associations are 
weakened due to the lack of the reinforcing cholinergic signal.  
 
Chapter 3 Summary 
 Detected cues evoked glutamatergic transients in all hit trials, irrespective 
of sequence. The amplitudes of glutamatergic transients in trials that ended with 
a hit were larger for longer cues. On signal trials resulting in a Miss, or CR, lever 
extension, representing the first indication that it is time to make a response also 
evoked a robust increase in glutamate release.  Furthermore, we compared the 
amplitudes of glutamatergic transients from trials yielding hits during periods of 
high levels of performance (SAT scores >0.35 averaged over all durations) with 
periods of near random performance (SAT scores: <0.35). The amplitudes of 
glutamatergic transients were markedly lower during poor performance periods 
(Fig. 3.7b). Furthermore, and in contrast to our hypothesis, lever extension 
evoked a glutamate release event on CR and Misses.     
  
Glutamate release events are not sequence dependent  
  
 Cholinergic transients are observed only on Hit trials that are preceded by 
CR and Misses. Glutamatergic transients are observed on all hits, regardless of 
sequence.  One possible means to selectively suppress cholinergic activity on 
  158 
HitHit sequences is inhibition presumably by GABAergic interneurons which 
are known to express both nicotinic and muscarinic acetylcholine receptors can 
act primarily to inhibit subsequent acitivation (Bandyopadhyay, Sutor, & Hablitz, 
2006; Disney & Aoki, 2008). Thus ACh release events suppress future release 
events via a GABAergic mechanism.  A second possibility is that synaptic 
spillover from the ACh release event on Hit trials activates presynaptic 
muscarinic M2 receptors attenuating subsequent release events.  As M2 
receptors are Gi coupled, signaling would decrease the probability of a second 
release event.  A third possibility is that there is a cholinergic release event on 
every Hit, but the release event on a HitHit sequence is more attenuated 
through mechanisms of habituation.  However, why this release event would be 
smaller, even though the glumatergic transient is not, is not supportive of this 
theory.   
 A final consideration concerns a mechanism that explains the carryover of 
the network shift between successive Hit trials. In combination with calcium influx 
presumably caused by glutamate release and activation of NMDA receptors, ACh 
release leads to sustained, persistent spiking of cortical neurons through 
activation of non-specific cation currents.  Such sustained spiking has been 
hypothesized to help effectively maintain stimulus-response contingencies and to 
serve as a preparatory mechanism for the next trial. This mechanism may also 
be capable maintaining prefrontal networks in a state that fosters cue detection 
(Fransen, Alonso, & Hasselmo, 2002; Hasselmo & Sarter, 2010; Hasselmo & 
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Stern, 2006).  Future studies will be needed to determine which, if any, of these 
mechanisms may be contributing to these differences. 
  
Future experiments, Chapter 3 
 The results from this experiment are very preliminary, therefore, the 
primary goal is to collect more data and verify that the present results are robust 
and reproducible.  One study that is necessary and is planned assesses the 
effects of mediodorsal thalamic lesions on SAT performance as well as 
cholinergic and glutamatergic transients in task-performing animals.   
 
Chapter 4 Summary 
 The main results of the behavioral and electrochemical experiments 
described above indicate that administration of a selective α4β2 nAChR agonist, 
but not nicotine, facilitates attentional performance under taxing conditions. 
Furthermore, compared with nicotine, the α4β2 nAChR agonist was more potent 
in evoking cholinergic transients which were characterized by very rapid 
termination of release, yielding "sharp" spikes in cholinergic activity. The more 
slowly rising and decaying transients evoked by nicotine are ‘sharpened’ by 
blocking the a7 nAChR; accordingly, we found that co-administration of nicotine 
with MLA robustly increased the Hit rate of dSAT-performing animals.  Results 
from trial-sequence analyses indicated that the beneficial performance effects of 
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the α4β2 nAChR were due to an increase in Hits in (signal) trials that followed 
either CR or Misses.         
 Combined, these findings are consistent with the hypothesis that such 
selective agonists enhance cue evoked glutamate release from mediodorsal 
thalamic afferents and in turn, enhance the probability of generating a cholinergic 
transient (in at least the subset of Hit trials requiring a shift from cue-independent 
to cue-dependent processing).  Nicotine should also enhance glutamate release 
through the same mechanism.  However, though its actions at the α7 nAChR it 
produces a long lasting release event. The exact mechanism underlying the α7 
nAChR’s ability to create extended release events is not clear.  Previous studies 
have explored the possibility that it is through an interaction with prefrontal 
dopaminergic inputs.  Removal of dopaminergic input to the PFC does attenuate 
the amplitude of α mediated ACh release, but not the long duration of the release 
event (Parikh, et al., 2010).  Further studies have demonstrated   that α7 nAChR 
stimulation leads to calcium induced calcium release (CICR), which could 
promote extended release (Dickinson, et al., 2008).  Regardless of the 
mechanism, as we have shown here, such long duration release events do not 
facilitate a precise cognitive operation like the shift from cue-independent to cue-
dependent processing.     
Future analyses, Chapter 4 
I plan to go back to my existing data set and conduct further analyses to 
determine if, like administration of the α4β2 nAChR, co-administration of nicotine 
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and MLA increase the possibility of a Hit in trials requiring a shift from cue-
independent to cue-dependent processing.   Furthermore, a more detailed 
analysis of SAT performance (including joint probabilities for Hits preceded by 
CR and Misses, as well as Hits preceded by Hits) following administration of 
nicotine will be undertaken.  One further possibility is that if cholinergic transients 
are indeed a learning signal, than perhaps by augmenting them there may be 
some carryover effects into the next day’s test session (i.e. perhaps performance 
on CRHit, MissHit trials the day after receiving the α4β2 agonist remains 
elevated).  Future analyses will examine this possibility as well.  
Concluding Remarks 
While much of the data in the current thesis remains preliminary, I have been 
able to provide new insight into the function of prefrontal cholinergic and 
glutamatergic mechanisms in the support of attentional performance.  Based 
upon the results of the study presented in Chapter 4, the current evidence also 
suggests that our combined electrochemical/behavioral approach may serve as a 
useful pre-clinical screening tool for the testing of compounds with putative 
cognition enhancing properties.   
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